

B4

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		A1	(11) International Publication Number: WO 96/34943 (43) International Publication Date: 7 November 1996 (07.11.96)
C12N 9/02, C12Q 1/26, A61K 31/00, 31/155, 31/35, 31/44, 31/20, 38/20, 38/18, 33/10			
(21) International Application Number: PCT/US96/06328		(74) Agents: FIGG, E., Anthony et al.; Rothwell, Figg, Ernst & Kurz, 555 13th Street, N.W. #701 East, Washington, DC 20004 (US).	
(22) International Filing Date: 3 May 1996 (03.05.96)		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/434,681 4 May 1995 (04.05.95)		US	Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(60) Parent Application or Grant (63) Related by Continuation US 08/434,681 (CIP) Filed on 4 May 1995 (04.05.95)			
(71) Applicant (for all designated States except US): CITY OF HOPE [US/US]; 1500 East Duarte Road, Duarte, CA 91010-0269 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): NADLER, Jerry, L. [US/US]; 2445 Upper Terrace Road, La Crescenta, CA 91214 (US). NATARAJAN, Rama [US/US]; 16837 East Dawn Haven Road, Hacienda Heights, CA 91745 (US).			

(54) Title: HUMAN LEUKOCYTE 12-LIPOXYGENASE AND ITS ROLE IN THE PATHOGENESIS OF DISEASE STATES

(57) Abstract

Evidence for the presence of a human leukocyte type of 12-LO enzyme and its role in the pathogenesis of several major disease states or processes, including atherosclerosis, breast cancer, autoimmune and inflammatory disease, diabetic vascular and kidney disease and insulin resistance is described. Mediation, including the blockage of the human leukocyte 12-LO expression or enzyme activation, provides novel treatment to prevent or ameliorate these disease states.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

HUMAN LEUKOCYTE 12-LIPOXYGENASE AND ITS
ROLE IN THE PATHOGENESIS OF DISEASE STATES

RELATED APPLICATIONS

This application is a continuation-in-part of U.S.
5 patent application Serial No. 08/434,681, filed 5 May
1995, which is a continuation-in-part of application
PCT/US94/00089, filed 4 January 1994, which is a
continuation-in-part of U.S. patent application Serial
No. 07/936,660, filed 28 August 1992.

10 GOVERNMENT RIGHTS STATEMENT

This invention was made with government support
under Grant No. DK 39721 RO1 awarded by the National
Institutes of Health. The government has certain
rights in the invention.

15 TECHNICAL FIELD

This invention pertains to a human leucocyte type
of 12-LO and its role in the pathogenesis of several
major disease states.

ABBREVIATIONS

20	AA	= Arachidonic acid
	AII	= Angiotensin II
	EGF	= Epidermal Growth Factor
	FN	= Fibronectin
	GAPDH	= Glyceraldehyde-3-phosphate dehydrogenase
25	GF	= Growth Factor
	HAEC	= Human Aortic Endothelial Cells
	HETE	= Hydroxyeicosatetraenoic Acid
	12 HETE	= 12-Hydroxyeicosatetraenoic Acid
30	HG	= High Glucose

-2-

	hl 12-LO	= Human Leukocyte 12-Lipoxygenase
	hl 15-LO	= Human Leukocyte 15-Lipoxygenase
	HODE	= Hydroxyoctadecadienoic acid
	12-HPETE	= 12-Hydroperoxyeicosatetraenoic Acid
5	HSMC	= Human Aortic Smooth Muscle Cells
	HPLC	= High Pressure Liquid Chromatography
	IL-1	= Interleukin-1
	LDL	= Low Density Lipoprotein
	LO	= Lipoxygenase
10	12-LO	= 12-Lipoxygenase
	15-LO	= 15-Lipoxygenase
	MAPK	= Mitogen Activated Kinase
	mmLDL	= Minimally Modified Low Density Lipoprotein
15	MO	= Monocytes
	NIDDM	= Non-insulin Dependent Diabetes Mellitus
	NG	= Normal Glucose
	PDGF	= Platelet Derived Growth Factor
	PKC	= Protein Kinase C
20	pl 12-LO	= Human platelet 12-Lipoxygenase
	PVSMC	= Porcine Vascular Smooth Muscle Cells
	RT-PCR	= Reverse Transcriptase Polymerase Chain Reaction
	SMC	= Smooth Muscle Cells
25	TGFB	= Transforming Growth Factor Beta
	TNF	= Tumor Necrosis Factor 1
	VSMC	= Vascular Smooth Muscle Cells

- 3 -

BACKGROUND OF THE INVENTION

The three mammalian lipoxygenases are named according to the carbon position (1, 2 or 3) at which they oxygenate arachidonic acid (4). There is increasing evidence that certain LO enzymes are involved in the pathogenesis and acceleration of atherosclerosis by inducing oxidation of LDL to its atherogenic form (5,6) and increasing the growth or migration of smooth muscle cells (1, 7-9). In addition, evidence suggests that a 12-LO protein plays a role in mediating angiotensin II (AII) induced vascular and adrenal actions (10-12). Recent studies indicate that at least two forms of 12-LO exist, i.e., p1 12-LO cloned from human erythroleukemia cells (2,13) and a porcine leukocyte 12-LO which has been isolated and cloned from porcine mononuclear cells, pituitary (14) and bovine tracheal cells (15).

Applicants have demonstrated the presence of a leukocyte type of 12-LO in human adrenal glomerulose cells (3). The human 15-LO has been purified from human and rabbit reticulocytes (16,17). The human platelet and porcine leukocyte type 12-LO share 65% amino acid homology (13). However, porcine leukocyte type 12-LO is highly homologous to human 15-LO (86%) (14). Recently, it has been shown that 15-LO is expressed in macrophages of human atherosclerotic lesions but not in unstimulated monocytes (18).

SUMMARY OF THE INVENTION

This application describes evidence for the presence of a human leucocyte type of 12-LO enzyme (hl 12-LO) and its role in the pathogenesis of several major disease states or processes, including atherosclerosis, breast cancer, autoimmune and inflammatory disease, diabetic vascular and kidney

- 4 -

disease and insulin resistance. There are several features of this unique enzyme that can link several seemingly diverse conditions.

1. hl 12-LO can utilize arachidonic and linoleic acid as fatty acid substrates generating hydroperoxides and other lipid mediators which can activate important signal transduction pathways commonly associated with these disorders. These mediators include (a) kinases such as specific isoforms of protein kinase C and mitogen activated kineses (MAPK), (b) transcription factors such as NFkB and oncogenes which have clearly been implicated in inflammatory and autoimmune conditions, atherosclerosis, cancer growth and metastasis.

2. Activation of the hl 12-LO enzyme can itself generate superoxide anions which can lead to the propagation of free radical processes which could accelerate the oxidative modification of lipids and proteins. These processes are involved in the pathogenesis of inflammatory, neoplastic and atherogenic conditions.

3. The hl 12-LO enzyme is strategically located. Evidence is presented showing the presence of the leucocyte type 12-LO in human monocytes, aortic vascular smooth muscle and endothelial cells, cardiac myocytes, skeletal muscle, the kidney and breast cancer cells and beta cells of pancreatic islets. These sites of activity of this enzyme allow a tissue specific role in leading to pathologic states. For instance, in the beta cells of the pancreatic islets, activation of 12-LO activity by inflammatory cytokines (e.g., IL-1) could explain the selective dysfunction and destruction of the beta or insulin producing cells of the pancreas. Furthermore, activation or increased expression of the

-5-

12-LO pathway by glucose in the beta cells could explain the dysfunctional secretion of insulin in the common form of adult diabetes (non-insulin dependent diabetes).

5 4. Factors increasing 12-LO expression and activity are linked to inflammatory, atherosclerotic, renal and neoplastic disease.

10 The factors demonstrated to increase the activity and expression of 12-LO include, (a) inflammatory cytokines associated with autoimmune disease (Type I diabetes) atherosclerosis and neoplastic growth such as interleukin-1 β (IL-1), (b) growth factors such as platelet derived growth factor (PDGF) and angiotensin II (AII) which have been implicated in accelerated 15 vascular and kidney disease, and (c) hyperglycemia which has been linked to the microvascular (eye, kidney and nerve) and macrovascular (heart attack, stroke and peripheral vascular disease) complications of both type I or type II diabetes.

20 5. Applicants have found that glucose which accounts for much of the acquired insulin resistance in diabetes increases 12-LO activity and expression in all tissues tested. Therefore, 12-LO activation could provide a common link between glucose-induced oxidative 25 stress and development of end-organ dysfunction or damage.

Pursuant to this invention, blockade of the h1 12-LO expression or enzyme activation provides novel treatments to prevent these disease states.

30 IDENTIFICATION OF 12-LO
IN NORMAL HSMC, HAEC AND MO

Applicants have now evaluated the precise type of LO present in unstimulated human aortic smooth muscle cells (HSMC), endothelial cells (HAEC) and monocytes

-6-

(MO). Furthermore, since AII can increase the expression of 12-LO in human adrenal cells, applicants have also evaluated the effects of AII on 12-LO regulation in HSMC. Finally, applicants determined 5 whether immunohistochemical analysis of atherosclerotic lesions demonstrates the presence of a leukocyte type of 12-LO. The results show that a 12-LO similar to that found in human adrenal glomerulose is expressed in the normal HSMC, HAEC and MO. Furthermore, this 12-LO 10 is markedly upregulated by AII in HSMC and is present in human atherosclerotic lesions.

DESCRIPTION OF FIGURES 1 TO 7

Figures 1A and 1B illustrate RT-PCR analysis of leukocyte 12-LO RNA in HAEC, HSMC, and MO. Figure 1A 15 illustrates RNA samples that were amplified for 40 cycles with leukocyte specific 12-LO primers. Membranes were hybridized with porcine leukocyte 12-LO oligonucleotide probe. Lane 1 is a marker, Lanes 2, 5, 8 are negative controls without template, lane 3 20 represents total RNA from HAEC, with porcine leukocyte 12-LO primer, lane 4 with GAPDH primers. Lane 6 represents total RNA from HSMC with porcine leukocyte 12-LO primers, lane 7 with GAPDH primers. Lane 9 represents total RNA from MO with porcine leukocyte 12- 25 LO primers. Lane 10 with GAPDH primers, and lane 11 is a positive control using the porcine leukocyte 12-LO cDNA.

Figure 1B illustrates the same RNA samples which 30 were amplified for 40 cycles with human specific 15-LO primers. Membranes were hybridized with human 15-LO oligonucleotide. Only the 333 base pair product from amplification of the 15-LO cDNA (positive control) is shown.

-7-

Figure 2 illustrates the expression of leukocyte 12-LO protein (72 kD) in normal HAEC, HSMC, and MO. Cytosol fractions from HAEC, HSMC, and MO were electrophoresed along with authentic porcine 12-LO protein and subjected to Western immunoblotting.

Figure 3A illustrates the effect of AII on 12-HETE release by HSMC. HSMC were grown to confluence. Serum was removed and cells were incubated in media 199 containing 0.4% fetal bovine serum (FBS) and 0.2% BSA for 18 hours. Cells were then washed with DME media and incubated for 20 minutes in DME media containing 0.2% BSA. AII was added to the cells for five and ten minutes at the concentrations of 10^{-9} and 10^{-8} mol/L. Media were collected for HETE assay.

* $p<0.05$ vs control n=4

Figure 3B illustrates the effect of AII on cell-associated 12-HETE levels in HSMC. After collecting supernatants, cells were washed with ice-cold PBS and harvested by scraping for the assay of cell-associated HETEs.

* $p<0.02$ vs control n=4

Figures 4A and 4B illustrate the regulation of leukocyte 12-LO protein expression by AII in HSMC. Figure 4A is an immunoblot showing regulation by AII. Figure 4B is a bar graph representation of densitometric analysis of immunoblot in Figure 4A. Cells were grown in medium 199 containing 20% FBS and serum-depleted for 24 hours by placing in medium 199 containing 0.4% FBS and 0.2% BSA. Cells were treated with AII at the concentration of 2×10^{-7} mol/L for 24 to 48 hours. Cells were washed with PBS and harvested by scraping. Cell pellets were lysed and cytosol fractions were electrophoresed.

Figures 5A and 5B illustrate the regulation of leukocyte 12-LO mRNA levels by AII in HSMC using RT-PCR. Figure 5A is the autoradiogram of the blot hybridized with 12-LO oligonucleotide probe. Figure 5B is etidium bromide stained agarose gel. Total RNA was extracted from culture HSMC incubated in low serum conditions with AII (2×10^{-7} mol/L) for different time-period shown. RNA samples were amplified for 40 cycles with leukocyte 12-LO primers or GAPDH primers.

Figures 6A and 6B illustrate microphotographs of a histologic section of an artery obtained from a below-the-knee amputation specimen from a patient with extensive arteriosclerosis. Avidin-biotin complex immunohistochemical technique was used to detect 12-LO with purified specific rabbit anti-sera. Intense staining of endothelial cells (arrowhead), cells present in endothelial thickening (small arrow) and, to a lesser degree, on the smooth muscle cells (larger arrow) were noticed in Figure 6A. Pre-immune rabbit sera was used at the same concentration s negative control (Figure 6B). (X 200 magnification).

Figures 7A and 7B illustrate immunostaining of human coronary lesions using antibody to 12-lipoxygenase. Shown is a cross-section of a human left coronary artery with an advanced atherosclerotic plaque (note the cholesterol crystals in the core region) reacted with either 12-LO antibody (Figure 7A) or pre-immune antisera (Figure 7B). The darkest immunoreactivity is seen in adventitial blood vessels associated with pericytes. The medial smooth muscles cells are also immunoreactive. Lighter immunoreactivity is seen in intimal cells in plaque and non-plaque areas.

EXPERIMENTAL PROCEDURE

The lipoxygenase (LO) pathway has been implicated in leading to accelerated atherosclerosis. The precise form of 12-LO expressed in adrenal glomerulose pancreatic islets is described in application PCT/US94/00089. This application establishes that a similar precise type of h1 12-LO is present in unstimulated human aortic smooth muscle cells (HSMC), endothelial cells (HAEC) and monocytes (MO). In this study, the specific reverse-transcriptase polymerase chain reaction (RT-PCR) method was used to analyze the type of LO mRNA expressed in normal HSMC HAEC and MO. In all three cell types, a 333 base pair band was seen using primers and probes specific for the leukocyte type of 12-LO suggesting that a leukocyte type of 12-LO is expressed in these cell types. Western immunoblotting analysis in cultured HSMC, HAEC and MO using a polyclonal peptide antibody to leukocyte type of 12-LO showed a specific 72 kD band which is identical to the molecular weight of the leukocyte type of 12-LO. Angiotensin II (AII) added to normal HSMC increased 12-LO activity and expression. Immunohistochemical analysis of atherosclerotic lesions also indicated the presence of a leukocyte type of 12-LO. These results indicate that a leukocyte type of 12-LO RNA is expressed in HSMC, HAEC and MO. Also, AII upregulates 12-LO activity and expression in HSMC supporting a role for this 12-LO pathway in human vascular disease.

30 1. Cells and cultures.

HAEC and HSMC were isolated from aortic specimens obtained from the heart donors in UCLA heart transplant program. HAEC at passages 5-9 and HSMC at passages 3-7 were used. HAEC were grown in medium 199 containing

-10-

20% FBS supplemented with EC growth supplement (20 mg/ml) and heparin (90 µg/ml). HAEC were identified by their typical cobblestone morphology, presence of Factor VIII-related antigen and uptake of acetylated LDL labeled with 1,1'-dioctadecyl-1-3,3',3'-tetramethylindo-carbocyanine perchlorate (Dil-acetyl-LDL) (19). HSMC were grown in medium 199 containing 20% FBS and identified morphologically and immunohistochemically using HHF35, which was then visualized by a fluorescently labeled second antibody or using a biotin-streptavidin complex immunoperoxidase system (20). Monocytes were obtained from a large pool of healthy donors by a modification of the Recalde method (21).

15 HSMC and HAEC monolayers were washed twice with ice-cold PBS and then processed for RNA extraction or western analysis as described below. For hydroxyeicosatetraenoic acid (HETE) assay, approximately 24 hours prior to an experiment, the medium was replaced with medium 199 containing 0.4% FBS and 0.2% BSA.

2. cDNAs.

Recombinant Bluescript plasmid containing the cDNA for human reticulocyte 15-LO was kindly provided by Dr. E. Sigal (Syntex Co., Palo Alto, CA). pUC19 plasmid containing the cDNA for porcine leukocyte 12-LO was obtained as described previously (14). Bluescript plasmid containing the cDNA for human platelet 12-LO was kindly provided by Prof. Bengt Samuelson (Karolinska Institute, Stockholm, Sweden) (2).

3. Oligonucleotide primers and probes for PCR.

β_2 -Macroglobulin oligonucleotides were a kind gift of Dr. Perrin White (Cornell University Medical College, New York, NY). Other oligonucleotides

-11-

including human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) oligonucleotides were synthesized on an Applied Biosystems (Foster City, CA) DNA synthesizer and were purified by polyacrylamide gel electrophoresis. The sequences of oligonucleotides are listed in Table 1 and were designed based on known gene sequences (2,14,22,23) and selected from regions displaying most divergence between porcine 12-LO and 15-LO sequences (13).

10

Table 1
Primers and probes for amplification and detection

			Sequence (5'-3')	Position
15	Human 15-LO	5' primer	AACTCAAGGTGGAACTACCGGAG (SEQ ID NO. 1)	146-168
		3' Primer	ATATAGTITGGCCCCAGCCATATTC (SEQ ID NO. 2)	453-477
20		Probe	AGGCTCAGGACGCCGTTGCC (SEQ ID NO. 3)	306-326
		5' Primer	TTCAGTGTAGACGTGTCGGAG (SEQ ID NO. 4)	145-165
25	Porcine Leuko- cyte 12-LO	3' Primer	ATGTATGCCGTGCTGGCTATATT (SEQ ID NO. 5)	451-477
		Probe	TCAGGATGCCGTGCCCTCCAC (SEQ ID NO. 6)	301-322
30	human GAPDH	5' Primer	CCCATACCACCTTCCAGGAG (SEQ ID NO. 7)	211-231
		3' Primer	GTTCTCATGGATGACCTTGGC (SEQ ID NO. 8)	475-495

-12-

	Probe	CTAAGCAGTTGGTGGTGCAGG (SEQ ID NO. 9)	446-466
	human platelet 5' Primer 12-LO	GATGATCTACCTCCAAATATG (SEQ ID NO. 10)	472-492
5	3' Primer	CTGGCCCCAGAACAGATCTGATC (SEQ ID NO. 11)	610-630
	Probe	GTTTGAGGGGCCATCTCCAGAGC (SEQ ID NO. 12)	544-565

4. Amplification of reverse transcribed RNA using
10 the polymerase chain reaction (RT-PCR).

Total RNA from cultured HSMC, HAEC and fresh MO was extracted with guanidium thiocyanate-phenol-chloroform using RNAzol (Cinna/Biotecx Laboratories International Inc., Texas). Some RNA samples were treated by RNase-free DNase. 3 microgram of total RNA was mixed with the PCR buffer (10 mmol/L Tris-HCl, pH 8.3, 50 mmol/L KCl, 1.5 mmol/L MgCl₂, and 0.001% gelatin), 200 μmol/L of each of the four deoxynucleotide triphosphates, 25 pmol each of 5'- and 3'-primers, 2 U Avian Myeloblastosis Virus 20 reverse transcriptase (20 U/μl; Life Sciences, St. Petersburg, FL), and 2.5 U Taq polymerase (Perkin Elmer Cetus, Norwalk, CT) in a final vol of 50 μl. In some reactions, 5 pmol of each 5'- and 3'-primer of β₂ macroglobulin or GAPDH were added as an internal standard. The samples were placed in a thermal cycler at 37°C for eight minutes for the RT reaction to proceed. Then conditions used for PCR were a denaturation step at 94°C for one minute, annealing at 50°C for two minutes, and extension at 72°C for two minutes for 20-40 cycles. Blank reactions with no RNA template were carried out through the RT and PCR steps. The human 15-LO cDNA, porcine leukocyte 12-LO cDNA, and human platelet

12-LO cDNA amplifications were carried out by mixing 2-5 ng cDNA plasmid in a 50 μ l vol containing 200 μ mol/L of each of the four deoxynucleotide trisphosphates, 25 pmole 5'-and 3'-primers, and 2.5 U Taq polymerase. The 5 conditions for PCR were the same as described before.

5. Gel analysis and blot hybridization.

20 μ l aliquots of the PCR products were subjected to electrophoresis in a 1.8% agarose gel in Tris acetate-EDTA buffer. After staining with ethidium bromide and 10 photographing, the gel was transferred onto a Zeta-probe membrane (Bio-Rad, Richmond, CA) by capillary blotting. The oligonucleotides used as probes were labeled at the 5'-end using [γ^{32} P]ATP and T4 polynucleotide kinase (New England Biolabs, Beverly, MA) and hybridized with 15 membrane overnight in 6x SSC (1 x SSC contains 0.15 mol/L NaCl, 0.015 mol/L sodium citrate), 0.5% non-fat dried milk and 7% SDS at 42°C. Membranes were washed once in 6 x SSC at room temperature for 15 minutes and then once at 60°C for 15 minutes. The washing conditions were 20 worked out to distinguish between the PCR products of human 15-LO from those of porcine leukocyte 12-LO (3). The filters were exposed to Kodak x-ray film (Eastman Kodak Co., Rochester, NY) with an intensifying screen at -70°C. Blots were quantitated using a computerized 25 video densitometer.

6. Western Immunoblotting.

Cells pellets were lysed in lysis buffer containing PBS (pH 7.3), 1% Triton X-100, 1 mmol/L phenylmethylsulfonyl fluoride, 50 μ mol/L leupeptin, 30 and 0.1% sodium dodecyl sulfate (SDS). Lysates were centrifuged at 10,000 x g for 10 minutes. An aliquot of the supernatant (cytosol) was saved for protein estimation and the remainder saved at -70°C for Western Blot analysis.

-14-

SDS polyacrylamide gel electrophoresis (10% running gel, 4% stacking gel) was performed according to the method of Laemmli (24). For Western blotting, gels were equilibrated in transfer buffer (35 mmol/L Tris base, 192
5 mmol/L glycine, and 20% methanol, pH 8.3) and then transferred to nitrocellulose (Hybond, Amersham, Arlington Heights, IL) as described by Towbin et al.
(25), in a semidry polyblot apparatus (American Bionetics, Inc., Emeryville, CA) for 40 minutes. The
10 nonspecific sites were blocked with PBS containing 10% of FCS at 4°C overnight. The membranes were then washed twice with PBST (PBS + 0.05% Tween-20) and incubated with primary antibody in PBST containing 1% BSA and 20% (vol/vol) FCS for 2 hours at room temperature. A
15 polyclonal antibody against porcine 12-LO peptide with the sequence of amino acids 646-662 of the porcine leukocyte 12-LO sequence (14) was used. This antiserum was used at 1:100 dilution. In some studies, a polyclonal antibody against human 15-LO kindly provided
20 by Dr. E. Sigal (Syntex Co., Palo Alto, CA) was used. The washed membranes were then incubated for 1 hour with second antibody (goat antirabbit) conjugated with alkaline phosphatase (1:5000; Promega, Madison, WI). Detection was either by color development using substrate
25 mixture (Nitroblue tetrazoleum and 5-bromo-4-chloro-3-indolyl phosphate from Promega) or by chemiluminescence using CSPD substrate and the Western-Light Chemiluminscent detection system (Tropix, Inc., Bedford, MA). Nonspecific binding was evaluated using normal
30 rabbit serum. Western blots were quantitated using a computerized video densitometer (Applied Imagining, Santa Clara, CA; Lynx DNA vision) and values expressed as arbitrary absorbance units.

-15-

7. Measurement of 12-LO products.

These assays were performed using previously published methods (10,11). Briefly, 12-and 15-HETE are extracted from supernatants and cells on C18 mini columns 5 (Analytichem International, CA) and measured using our validated reverse phase gradient HPLC and (RIA) methods.

8. Measurement of lipoxygenase activity in HSMC.

Confluent HSMC were placed in media plus 10% FCS 24 hours prior to the experiment. The cells were harvested, 10 washed, suspended in 1 ml Tris-HCl buffer (25 mmol/L, pH 7.7) and then sonicated on ice. The assay mixture contained in 1.0 ml, 800 μ l enzyme (sonicate), 100 μ l CaCl₂ (1.5 mmol/L) and 50 μ l glutathione (0.5 mmol/L). An enzyme blank was run simultaneously. The reaction was 15 started at 37°C with 50 μ l sodium arachidonate (160 μ mol/L Nu Check Prep, Elysain, MN) or 0.25 μ Ci¹⁴[C] linoleic acid (New England Nuclear). After 10 minutes incubation, the reaction was stopped with 2 ml isopropanol/1.2% acetic acid followed by 2 ml chloroform. 20 The lower organic layer was filtered and subjected to HPLC to detect HODEs or HETEs using applicants' gradient reverse phase HPLC system (10,11). 12-HETE peak was identified by UV detection at 237 nM and co-migration with authentic standard (retention time 18.3 minutes). 25 Peak heights were quantitated using a Shimazu CR5A integrator. For the identification of radioactive linoleic acid metabolites, ¹⁴[C] HODEs, radioactivity in the fraction co-migrating with the same retention time as the authentic cold HODEs was quantitated. In this HPLC 30 system, both 9- and 13-HODE have the same retention time (17.9 minutes).

9. Immunohistochemistry.

The immunohistochemical method used has been previously described (26). Briefly, five micron sections

of tissue samples derived from a lower extremity amputation for peripheral vascular disease or a coronary artery showing an atherosclerotic plaque were mounted on Silane (3-Aminopropyltriethoxysilane, Sigma, St. Louis, MO) coated slides and dried overnight at 60°C. After deparaffination and dehydration they were placed in a 10 mmol/L citrate buffer solution (pH 6.0) and boiled in a microwave oven for two periods of 5 minutes each. After cooling, the sections were twice washed in distilled water. Following a 20 minute incubation in 1% hydrogen peroxide/methanol, the slides were washed twice in distilled water and twice in phosphate buffered saline (PBS). This was followed by blocking with normal horse serum 1:20 in PBS (Vector Labs). After decanting, the sections were covered with rabbit peptide anti-leukocyte 12-lipoxygenase antisera at 1:1000 dilution and incubated overnight in a humid chamber at room temperature. After two washes in PBS the slides were incubated for 40 minutes with biotinylated anti-rabbit IgG (Elite kit, Vector Labs, Burlingame, CA) at 1:600 dilution. After two additional washes in PBS the sections were incubated in AB complex (Elite kit, Vector Labs) at 1:200 dilution for another 40 minutes. The sections were then exposed to a Diamino benzidine solution for 7 minutes for color development. After two additional washes, the color was enhanced by incubating the sections in 1% copper sulfate for 5 minutes. All the steps were performed using an automatic stainer (Techmate 1000, Bioteck Solutions, Santa Barbara, CA). Sections from the peripheral vessel were washed again and lightly counter stained in 6% Mayer's hematoxylin, washed, dehydrated and coverslipped. The sections from the coronary artery were not counter stained. Control slides were prepared by substituting

-17-

anti-12-lipoxygenase with pre-immune rabbit serum at the same concentration.

10. Data analysis.

Immunoblots and autoradiograms were analyzed using a computer driven densitometer (Applied Imaging, Santa Clara, CA; Lynx DNA Vision). Data shown is representative of two to three experiments. Data generated from AII treatment of HSMC for 12-HETE synthesis was analyzed using ANOVA for multiple samples using a statistical package on a Macintosh computer system. Data is presented as mean \pm SE.

RESULTS OF EXPERIMENTAL PROCEDURES

Expression of a leukocyte type of 12-LO mRNA in HAEC, HSMC, and MO.

15 The expression of 12-LO mRNA in HAEC, HSMC and MO was evaluated using a specific RT-PCR method since the level of detection was below the sensitivity of Northern analysis. Figure 1A shows expression of leukocyte 12-LO mRNA in normal HAEC, HSMC, and MO using a method highly 20 specific for this form of 12-LO mRNA. The appropriate 333 base pair band was seen in all three cell types.

Figure 1B demonstrates RT-PCR analysis of human 15-LO mRNA expression from the same RNA. These results 25 reveal no evidence for a band characteristic of human 15-LO. In a separate experiment, RNA from HAEC, HSMC, and MO was amplified and probed for the platelet type 12-LO RNA. No evidence for a human platelet 12-LO expression was found (data not shown).

Expression of hl 12-LO protein in HAEC, HSMC and MO.

To investigate whether a leukocyte type of 12-LO enzyme was expressed in vascular and circulating MO, the 10,000 xg supernatant proteins were electrophoresed and subjected to Western analysis using a polyclonal peptide

-18-

antibody derived from a sequence in the porcine leukocyte type of 12-LO that is homologous to the sequence of 12-LO found in human adrenal glomerulose. This antibody has previously been shown to lack cross reactivity to the 5 platelet form of 12-LO and successfully demonstrated the presence of a leukocyte type 12-LO in human adrenal cells (3). Figure 2 demonstrates a major 72 kD band from Western analysis in HSMC, HAEC, and MO. Western analysis similarly performed using a polyclonal antibody directed 10 against the human 15-LO protein did not demonstrate a band in the expected molecular weight form these cells (data not shown). HAEC and MO produced 12-S-HETE as reflected by HPLC and RIA analysis (HAEC 2386, MO 820 pg/ 10^6 cells). Results for HSMC are detailed below.

15 Therefore, HSMC, HAEC and MO appear to express a 12-LO protein which is similar to the leukocyte type of 12-LO found in porcine tissues and human adrenal glomerulose.

20 Effect of AII on 12-LO activity and expression in HSMC and certain other tissues.

Another major aspect of this invention is the discovery that AII increases the activity and expression of 12-LO mRNA and protein in HSMC. Figure 3A shows that 5 minute incubation of HSMC with AII at the 25 concentrations of 10^{-8} mol/L and 10^{-9} mol/L in serum free media stimulates the release of 12-HETE (control: 599 ± 105 ; AII 10^{-8} M: 1467 ± 277 ; AII 10^{-9} mol/L: 1296 ± 262 pg per mg of protein). Ten minute incubations with AII also significantly stimulated the release of 12-HETE at the 30 concentration of 10^{-8} mol/L. AII significantly also increased cell-associated 12-HETE levels in HSMC (Figure 3B). In other studies, it was found that 12-HETE levels in response to AII could be reduced by the LO inhibitor baicalein 10^{-5} mol/L (data not shown).

To examine whether AII induces the 12-LO enzyme expression in HSMC, cells were treated with AII at the concentration of 2×10^{-7} mol/L for 24 or 48 hours. The 12-LO protein was identified by Western immunoblotting 5 using a specific antibody to purified leukocyte type 12-LO or a peptide antibody derived from known sequences present in the human leukocyte type of 12-LO. A distinct band was detected with a molecular weight of nearly 72 kD which is the reported molecular weight of the porcine 10 leukocyte-type of 12-LO (Figure 4). A 24 hour incubation of HSMC with AII in serum free media induced nearly a seven fold increase in 12-LO protein expression (Figure 4). In other experiments, AII was added for 48 hours also induced 12-LO expression 4-7 fold (data not 15 shown).

In order to evaluate the specific expression and regulation of 12-LO mRNA in HSMC, applicants used a RT-PCR assay that exclusively amplifies the leucocyte type of 12-LO. The size of the PCR amplified fragment is 333 20 bp for both 12- and 15-LO. Therefore, specific conditions were used to distinguish leukocyte type 12-LO and human 15-LO by increasing stringency and raising washing temperature to 60°C. Figure 5A shows a Southern blot analysis of RT-PCR amplified products from HSMC 25 serum-deprived for 24 hours and then treated for the indicated times with AII 10^{-7} mol/L. In this experiment, very low basal expression of 12-LO is seen. However, in other experiments in cells from various other donors, basal 12-LO expression is detectable with PCR at 20-30 30 cycles. AII induces 12-LO mRNA expression starting at the 12 hour incubation time and the maximum induction is shown at 36 hour incubation of cells with AII. Figure 5B shows the ethidium bromide stained agarose gel showing the amplification of GAPDH as an internal marker. When

-20-

PCR conditions were used that were specific for either the platelet type 12-LO or human 15-LO no specific RNA band was detected (data not shown). Therefore, basal serum deprived HSMC show low expression of a leukocyte 5 type 12-LO which is markedly upregulated by AII.

The leukocyte type of 12-LO, unlike the platelet form can also metabolize linoleic acid. Therefore, applicants evaluated whether the HSMC could form 13-HODE, the linoleic acid metabolite of LO action in addition to 10 12-HETE, the product of arachidonic acid metabolism. The 15 accomplish this, applicants performed separate experiments in which the appropriate cytosolic fractions of HSM were treated with either C¹⁴ linoleic acid or cold arachidonic acid and the LO products of the HSMC were analyzed by a gradient reverse phase HPLC system. Cells 20 labelled with cold arachidonic acid showed HPLC peaks co-migrating with 12-HETE. The peak height in the cell blank sample was 1.5 cm which increased to 3/5 cm in the HSMC sonicate. Cells incubated with C¹⁴ linoleic acid also produced 13-HODE (695 counts per minute blank to 25 1038 counts HSMC sonicate).

To evaluate whether a leukocyte type of 12-LO is present in atherosclerotic lesions, immunohistochemistry was performed using the peptide anti-leukocyte type 12-LO 25 antibody. Figure 6A represents a high power section derived from a lower extremity amputation specimen from a patient with peripheral vascular disease. Specific 30 cytoplasmic staining for leukocyte type of 12-LO is evident in both the endothelial and smooth muscle layers of this lesion. The neointimal area also demonstrates staining for leukocyte type 12-LO. Figure 6B represents a high power section from the same lesion stained with pre-immune antisera. This section demonstrates minimal background staining suggesting that the staining for

-21-

leukocyte type 12-LO in Figure 6A is specific. Figure 7 is a representative section from a left human coronary artery showing an advanced atherosclerotic lesion. Figure 7A shows definite staining for 12-LO protein in 5 the smooth muscle and adventitial areas as well as endothelial cells. Figure 7B represents immunohistochemistry with the pre-immune antisera showing very little background staining with this antibody. These results demonstrate that a 12-LO RNA and 10 protein similar to that found in porcine leukocytes and human adrenal glomerulose (3) is also expressed in human vascular cells and circulating monocytes. Several approaches were utilized in this current investigation to support this conclusion. First, a peptide antibody 15 derived from a sequence common to the porcine and human form of leukocyte type of 12-LO revealed a characteristic 72 kD band in HSMC, HAEC and MO lysates. This antibody does not cross react with the platelet form of 12-LO but has partial cross reactivity with human 15-LO (3). 20 Second, a highly specific RT-PCR procedure was used to detect 12-LO mRNA in these cell types. In a previous study, it was demonstrated using this technique that a leukocyte type of 12-LO was the exclusive type of 12-LO seen in human adrenal glomerulose and U937 cells (3). In 25 the present study, a specific 333 base pair amplified mRNA product was found in unstimulated HSMC, HAEC and MO when appropriate leukocyte type 12-LO primers and probe were utilized. Thirdly, in all three cell types, the 12-LO product 12-S-HETE was formed as reflected by HPLC and 30 specific RIA. The cytosol from HSMC reacted with both arachidonic and linoleic acid to produce either 12-HETE or 13-HODE respectively. This reaction is characteristic of a leukocyte type of 12-LO and not the platelet 12-LO

which only reacts with arachidonic acid to produce 12-HETE.

The human 15-LO originally cloned from the reticulocyte and found in human trachea is highly homologous (86% sequence homology) to the porcine leukocyte type of 12-LO (14). The PCR technique utilized here can distinguish between the leukocyte 12-LO and the 15-LO (3). The specificity of this approach was demonstrated using the 12-LO and 15-LO cDNA as templates for amplification (3). Therefore, the Southern blot hybridization using the leukocyte 12-LO probe provides the strongest evidence that the band seen reflects a 12-LO and not a 15-LO amplified product. These results are in agreement with previous studies showing no detectable 15-LO mRNA in basal or stimulated human endothelial or non-stimulated mononuclear cells (27). However, 15-LO mRNA and protein has been found in macrophage rich areas of atherosclerotic vascular lesions and in IL-4 stimulated monocytes (28) suggesting that 15-LO can play a role in advanced atherosclerotic and immune mediated vascular disease.

Increasing evidence also suggests that a 12-LO enzyme plays an important role in AII-induced actions in several additional tissues. Studies suggest that the 12-LO pathway of arachidonic acid can mediate AII-induced aldosterone synthesis in rat and human adrenal glomerulose cells (11,12). Furthermore, recent data indicates that AII-induced adrenal cell proliferation is mediated at least in part by activation of a 12-LO enzyme. Additional studies in the rat have implicated the 12-LO pathway in the vasoconstrictive and renin-inhibitory actions of AII (29). The aorta has the capacity to produce LO products including 12 and 15-HETE (30). Recent data has revealed that both AII and high

-23-

glucose can up-regulate the leukocyte type of 12-LO in cultured porcine aortic smooth muscle cells (31).

AII has major effects on vascular smooth muscle cell growth in vitro and in vivo (1,7, 32-34). In a recent 5 report, it was found that a relatively selective 12-LO inhibitor but not a cyclooxygenase inhibitor could completely prevent AII-induced hypertrophic responses in cultured porcine vascular smooth muscle cells (35). Furthermore, 12-HETE induced similar increases in protein 10 and fibronectin content of these vascular smooth muscle cells as AII (36). The 12-LO pathway and its product 12-HETE has also been implicated in vascular smooth muscle cell migration (9). 12-HETE at concentrations as low as $10^{-12}M$ have been shown to lead to smooth muscle cell 15 migration. Additional studies have demonstrated that 12-LO products can activate specific isoforms of protein kinase C and oncogenes including ras, c-fos and jun (36-38).

Increased 12-LO activity and expression by AII may 20 therefore be a previously unrecognized mechanism for AII-induced hypertensive and atherosclerotic vascular disease in humans. Accordingly, another important aspect of this invention entails blockade of the 12-LO pathway as a novel therapeutic modality to reduce AII related 25 cardiovascular disease.

The 12-LO pathway in the human vascular wall and monocytes may participate in other mechanisms related to the development or progression of atherosclerotic vascular disease. Recent evidence has implicated a LO 30 pathway in oxidative modification of LDL in the vascular wall (39-41). It is now clear that HAECC, HSMC or monocytes have the capacity to convert native LDL to minimally modified LDL which has a greater atherosclerotic potential. Of interest is the data

-24-

showing that cholesterol loading of macrophages primarily leads to increased production of 12-HETE (42). A recent report has now demonstrated that both the leukocyte type of 12-LO and 15-LO can similarly oxidize lipoproteins
5 (42). Interestingly, this same report showed a lack of ability of the platelet 12-LO to oxidize lipoproteins.

To provide additional evidence for the presence and localization of a leukocyte 12-LO in human vessels, immunohistochemical analyses of two atherosclerotic
10 lesions were performed. The results provide immunohistochemical evidence that a leukocyte type of 12-LO is particularly expressed in the endothelial and smooth muscle cells of an atherosclerotic lesion supporting a potential role of this pathway in the early
15 progression of atherosclerotic vascular disease. Previous studies have shown that vascular tissues and monocytes have LO activity (42-44).

Pathways by which AII and 12-HETE Function

It has now been discovered that AII and 12-HETE
20 effect changes in cells by stimulating mitogen activated protein (MAP) kinase activity. Specifically, AII and 12-HETE function by activating transcriptional activity of fos via ERK (extracellular regulated kinases) (e.g., ERK 1 ($P44^{MAPK}$), ERK 2 ($P42^{MAPK}$) and ERK3 ($P62^{MAPK}$)), by
25 activating jun via JNK (cJun kinases or stress activated kinases) and/or by activating JAK (Janus kinases e.g., JAK1 and JAK2). More specifically, AII and 12-HETE activate P-21 activated kinase (PAK), which has been implicated as a key upstream signal for JNK activation.
30

Experimental Procedures

ERK Activity: ERK activity was evaluated by the substrate-SDS-polyacrylamide gel method described in Anal. Biochem., 183:139-143 (1989). Confluent cells in 100 mM dishes were made quiescent in serum-free medium

-25-

and then treated with agonists for various time periods. The cells were then lysed in lysis buffer (1% NP40, 1% sodium deoxycholate, 0.1% SDS, 100 mM NaCl, 50 mM Tris, 10 mM EDTA, 1 mM EGTA, aprotinin, 100 mg/ml leupeptin, 5 0.1 mM PMSF and 1 mM sodium orthovanadate, pH 7.4). Lysates were centrifuged to pellet nuclei and the cell extracts (15-20 mg protein) were subjected to electrophoresis on SDS-polyacrylamide gels (10%) containing myelin basic protein (0.5 mg/ml) as an ERK 10 substrate. The SDS was then washed, followed by denaturation, renaturation and protein phosphorylation on the gel with [³²P] ATP.

JNK Activity: The plasmid pGEX-cJun 1/79 (Dept. Pharmacol. UCSD, La Jolla) is a GST-cJun (1-79) expression vector encoding amino acids (1-79) of cJun. 15 The GST fusion protein expression vector was transformed into E. Coli. Protein was induced with 0.1 mM IPTG and purified by affinity binding to glutathione-agarose beads. Unstimulated or stimulated cells were lysed into 20 WCEB (25 mM HEPES, pH 7.7, 0.3M NaCl, 15 mM MgCl₂, 0.2 mM EDTA and 0.1% triton X-100). About 50 µg protein extract was incubated with GST-cJun+GSH agarose overnight at 4°C. Phosphorylation was carried out at 30°C for 20 minutes in the presence of 20 mM HEPES, pH 7.5, 20 mM 25 b-glycerophosphate, 10 mM p-nitrophenolphosphate, 10 mM MgCl₂, 10 mM DDT, 50 µg Na₃VO₄, 20 µM ATP (cold) and about 0.5 µl of new gamma ³²P-ATP. After boiling with electrophoresis sample buffer, the supernatants were analyzed on 12% SDS-PAGE. JNK activity was also measured 30 by immunoprecipitation method using an anti-JNK antibody (Parmingen Co., San Diego) and then activities were measured using 2 µg of GST-cJun (1-79) as substrate as described in Cell, 81:1147-1157 (1995).

-26-

PAK Activity: Cell lysis and PAK activity measurement were performed as described in Science, 269:221-223 (1995). Cells were lysed on ice in 50 mM Tris-HCl, 150 mM NaCl, 5 mM EGTA, 50 mM NaF, 10 mM Na pyrophosphate, 1% NP-40, 2.5% glycerol, and 1 mM Na₃VO₄ (pH 7.5), containing protease inhibitors PMSF, leupeptin and aprotinin. Cell were centrifuged for 10 minutes at 1000 g. For immunoprecipitation, the supernatants were incubated with anti-PAK1 or anti-PAK2 antibody (1:25) (Dept. Immuno. & Cell Biology, Scripps Res. Instit., La Jolla, CA) for 2 hours at 4°C followed by incubation with 60 µl of 1:1 protein A beads for 60 minutes, then 5 X 1.0 ml lysis buffer washes and 2 washes with kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl₂ 0.2 mM dithiothreitol, 2 µg myelin basic protein and 14 Mµ [r-³²P] ATP) for 20 minutes at 30°C. The reaction was stopped with SDS sample buffer, and results were visualized by SDS-PAGE and autoradiography.

Results

20 It has been discovered that the administration of AII results in biphasic activation of MAP kinase (all of the MAP kinase experiments were conducted in CHO-AT1a cells -- AII receptor AT1a CDNA transfected Chinese hamster ovary cells). It has been found that AII (10⁻⁷M) 25 induces a biphasic stimulation of ERK activity with a first peak of activity at 5 minutes (2-6 fold) and a later peak at 3-4.5 hours (1.5-3 fold) as well as a stimulation of JNK activity which peaks at 30 minutes and remains sustained for 1 hour. It has also been found 30 that AII (10⁻⁷M) induces stimulation of PAK with one major peak at 30 minutes (5 fold).

It has also been discovered that 12-HETE (10⁻⁷M) induces a biphasic stimulation of ERK activity with a first peak at 5 minutes and a second peak at 3-4.5 hours

-27-

as well as a biphasic stimulation of JNK activity with peaks at 30 minutes (2-3 fold) and 3 hours (2.5-5 fold). It has been found that 12-HETE stimulates JNK activity at concentrations as low as 10^{-9} M, as shown in Figure 29.

5 It has further been discovered that 12-HETE induces stimulation of JAK activity. CHO-AT_{1a} cells were treated with 12-HETE (10^{-7} M) for 10 hours, immunoprecipitated with a phosphotyrosine antibody and immunoblotted using specific JAK1 and JAK2 antibodies. As can be seen in
10 Figure 30, 12-HETE increased JAK activity.

Finally, it has been discovered that 12-LO inhibitors (e.g., CDC and baicalein) dose-dependently reduce AII- and 12-HETE-induced mitogenic activities. Thus, the administration of a 12-LO inhibitor decreases AII-
15 and/or 12-HETE-induced MAP kinase activity, thereby decreasing the effects which AII and/or 12-HETE have on cell growth and development.

Consistent with this data, one aspect of the present invention entails therapy for AII- or 12-HETE-induced disease in humans which includes reducing ERK, JNK and/or JAK activity via the administration of a 12-LO inhibitor. While not wishing to be bound by a particular theory, it is believed that 12-HETE increases MAP kinase activity through upregulation of 12-HETE receptors. Thus, therapy
20 for AII- or 12-HETE-induced disease also includes reducing mitogenic activity via the administration of a 12-HETE receptor antagonist such as, for example, DUP654.

Inhibition of the 12-LO Pathway

The utilization of various pharmacologic, antisense
30 or ribozyme methods to reduce leukocyte type 12-LO activity is described in application PCT/US94/00089. Panaxynol, a polyacetylene compound isolated from ginseng has been identified as a relatively selective inhibitor

-28-

of leukocyte 12-LO (55) and is useful for the purpose of this invention.

Role of The 12-LO Pathway in
Breast Cancer Cell Growth

5 Example V of application PCT/US94/00089 indicates that blockage of the 12-LO pathway provides useful human breast cancer therapy. A further evaluation of the regulation of 12-LO activity and expression in breast cancer cells and tissues confirms that proliferation of
10 breast cancer tissue is inhibited by 12-LO inhibitors. Specifically, leukocyte-type 12-LO mRNA expression was studied by a specific reverse transcriptase PCR method in matched normal unininvolved and cancer involved breast tissue RNA samples from six patients. It was observed
15 that in each of the six patients, the cancer involved section showed a much higher level of 12-LO mRNA (340 bp PCR product) than the corresponding normal section (3-6 fold higher after normalization to the internal control for PCR, GADPH mRNA 284 bp). 12-LO mRNA levels were
20 also 7- and 11-fold greater in two breast cancer cell lines, MCF-7 and COH-BR1 compared to the normal breast epithelial cell line, MCF-10F. In addition, the proliferation of MCF-7 cells was significantly inhibited by three LO inhibitors, baicalein (10 μ M), CDC (10^{-5} M) and
25 NDGA (30 μ M), but not by a cyclooxygenase inhibitor, ibuprofen (10^{-5} M). Treatment of serum-starved MCF-7 cells with EGF for four hours lead to a dose dependent increase in the formation of the 12-LO product, 12-HETE (basal 257 \pm 10 pg/10⁶ cells; EGF 50 ng/ml 462 \pm 15 pg; EGF 100 ng/ml
30 593 \pm 46 pg, both p<0.001 vs basal). EGF (50 ng/ml) also led to a marked increase in the levels of the 12-LO protein (72 kD) as well as 12-LO mRNA at 24 hours. Hence, activation of the 12-LO pathway appears to play a

-29-

key role in basal and EGF-induced breast cancer cell growth and development.

Role of the 12-LO Pathway
in the Action of Estrogen in Breast Cancer

5 It has now been discovered that estrogen, which has been linked to breast cancer cell growth and development, plays a role in activating the 12-LO pathway in breast cancer cells.

Treatment of cells from the estrogen receptor
10 positive breast cancer cell line, MCF-7, with 17β -estradiol for 4 hours in a defined serum-free and phenol red-free medium led to a dose-dependent increase in the levels of cell associated 12-LO product 12-hydroxyeicosatetraenoic acid (12-HETE) (Basal 161 ± 29 pg/ 10^6 cells; 17β -estradiol, 5 nM 784 ± 150 pg; 17β -estradiol, 10 nM 1056 ± 187 pg; both p<0.001 vs basal). This stimulatory effect of 17β -estradiol on 12-HETE was not observed in the estrogen receptor negative cell line MDA-MB-231. Treatment of MCF-7 cells with estrogen for
20 22 hours also caused a dose-dependent increase in the expression of the leukocyte-type 12-LO protein as examined by immunoblotting with a 12-LO peptide antibody (2.1-fold and 3-fold increase over basal at 1 nM and 10 nM 17β -Estradiol respectively). Thus, 17β -estradiol increased 12-LO activity and expression in MCF-7 cells.
25 Hence, activation of the 12-LO pathway appears to play a key role in estrogen-induced breast cancer cell growth and development.

Consistent with this data, one aspect of this
30 invention entails therapy to reduce breast cancer cell growth and development through inhibition of the 12-LO pathway. Such 12-LO pathway inhibition would, *inter alia*, reduce the effect estrogen has on breast cancer cell growth and development.

-30-

Role of the 12-LO Pathway
in The Formation of VEGF

Applicants have also discovered that the 12-LO pathway plays a role in the formation of vascular 5 endothelial growth factor (VEGF). VEGF is an endothelial cell-specific mitogen which increases vascular permeability and monocyte migration. VEGF appears to be a major angiogenic factor for many types of cancer, including breast and lung cancer. Further VEGF has been 10 linked to the development of proliferative diabetic retinopathy as well as accelerated vascular disease often associated with diabetes.

Description of Figures 8, 9 and 10

Figure 8 illustrates the dose-dependent effect of 15 platelet-derived growth factor (PDGF) on vascular endothelial growth factor (VEGF) protein (42 kD) expression in MCF-7 breast cancer cells. Nearly confluent MCF-7 cells were serum starved for 24 hours by placing in DME medium + 0.4% FCS and 0.2% BSA. This 20 medium was then freshly replaced and the cells incubated for another 24 hours with PDGF. At the end of the incubation, the cell monolayers were washed with ice-cold PBS, scraped into PBS and pelleted by centrifugation. The cell pellets were then lysed and equal amounts of 25 protein (50 µg) subjected to electrophoresis and immunoblotting to detect VEGF using a specific antibody from Santa Cruz Biotechnology. Detection was by a chemiluminiscent technique. It is clearly seen that PDGF causes a dose-dependent increase in the expression of 30 VEGF in the breast cancer cells.

Figure 9 illustrates the effect of epidermal growth factor (EGF) and the 12-lipoxygenase product 12-HETE on VEGF protein expression in the MCF-7 breast cancer cell line MCF-7. MCF-7 cells were treated with EGF and 12-

-31-

HETE for 24 hours and VEGF protein identified as described in the legend to Figure 8. The figure shows that VEGF protein expression is not only induced by a breast cell mitogen such as EGF but also by the 12-LO product, 12-HETE. In fact, 12-HETE appears to be more potent than EGF in inducing VEGF indicating that 12-HETE has potent angiogenic properties.

Figure 10 illustrates the effect of a 12-lipoxygenase product 12-HPETE on VEGF protein (42 kD) expression in an immortalized human aortic smooth muscle cell line (AIHSMC). The cells were serum starved for 24 hours and then placed in fresh medium along with 12-HPETE. Cells were incubated for five hours and VEGF protein was then identified in cell lysed as described in the legend to Figure 8. Lane 3 shows that the 12-LO product, 12-HPETE causes an increase in the expression of the angiogenic agent, VEGF, in PVSMC when compared to the control in lane 1 as indicated in the figure.

Figures 8 and 9 report data in two human breast cancer cell lines MCF-7 and MDA MB that show that the 12-LO product 12-HETE at 10^{-7} M and 10^{-8} M increases VEGF protein expression. Figure 10 shows that 12-HETE can increase VEGF protein in HVSMC.

In addition to the work reflected in Figures 8-10, it has now been discovered that AII, 12-HETE and hyperglycemia (HG) increase VEGF production in vascular smooth muscle cells (VSMC). Porcine and human VSMC were cultured for at least two passages under normal glucose (NG, 5.5 mM) or under HG conditions. VEGF protein expression was determined by Western blotting and VEGF mRNA by Northern blots. HG alone increased the level of VEGF mRNA (2.8-fold) and protein (3.2-fold). In addition, VEGF protein (45 K) and mRNA (3.7 Kb) expression were markedly increased by 4 hours of

-32-

treatment with AII (10^{-7} M) in the cells cultured in HG (2.2- and 1.4-fold resp.). Furthermore, 12-HETE (10^{-8} M and 10^{-7} M for 4 hours) increased the expression of both VEGF protein and mRNA in cells cultured under both NG as well as HG conditions. In addition, HG increased the secretion of VEGF into the medium as measured by a specific EIA (56.2 ± 4 ng/ml NG vs 73 ± 5 HG, $p<0.02$). AII and 12-HETE also increased VEGF secretion by 1.24 and 1.4-fold, respectively, as measured by EIA.

10 Consistent with this data, one aspect of this invention entails therapy to reduce breast and other cancer metastatic potential as well as afflictions associated with diabetes (e.g., proliferative diabetic retinopathy and accelerated vascular disease) by reducing 15 VEGF production, for example, through inhibition of the h1 12-LO pathway.

Role of the 12-LO Pathway in
The Pathogenesis of Type I Diabetes

20 This aspect of this invention involves the role of 12-LO pathway activation in the pancreatic beta cell dysfunction or cytotoxicity in response to cytokines implicated in the pathogenesis of type I diabetes.

Description of Figures 11, 12 and 13

Figure 11 illustrates the effects of 12-LO products 25 on DNA synthesis in the insulin-producing rat beta cell line, RINm5F. DNA synthesis was studied using 3 H-thymidine incorporation (1uCi/ml) added for the last six hours (18-24 hours of experiment). The LO products were added to the cells in complete growth media for 24 hours. 30 As demonstrated, 12-hydroxyeicosatetraenoic acid (12-HETE, 10^{-9} M) and 12-hydroperoxyeicosatetraenoic acid (12-HPETE) reduced 3 H-thymidine incorporation reflecting their effects to decrease DNA synthesis in this beta cell line.

-33-

Figure 12 illustrates a western immunoblot of proteins isolated from the insulin producing rat beta cell line, RINm5F showing the effect of interleukin-1 β on 12-LO protein expression. In these studies, 25 μ g of protein was isolated from the cells grown for 16 hours in reduced serum-containing medium 0.4% alone or along with IL-1 β (0.1 ng/ml). The results demonstrate a 2-fold increase in 12-LO protein expression after IL-1 treatment (lanes 2 and 4). Lane 7 shows the 12-LO standard showing the characteristic 72 kD 12-LO protein band using applicants peptide antibody which recognizes the rat, porcine and human forms of leukocyte-type 12-LO.

Figure 13 illustrates the effects of IL-1 β on 12-HETE production in rat islets.

Applicants have discovered that direct addition of the 12-LO products 12-S-HETE or 12-HPETE directly decreases cellular growth as reflected by decreased 3 H thymidine incorporation or DNA synthesis in the rat pure beta cell line RIN-M5F. As shown in Figure 11, concentrations of 12-LO products even as low as 10 $^{-9}$ M decrease DNA synthesis. Figure 12 demonstrates that human IL-1B at 0.2 ng increases leukocyte 12-LO protein expression approximately two fold in these RIN cells. Figure 13 shows that IL-1B at 2.5 ng/ml markedly increases 12-LO activation in freshly isolated rat pancreatic islets as reflected by an increase in immunoreactive release of 12-S-HETE (92 pg/ml/40 islets basal to 250 pg/ml/40 islets.

-34-

Role of The 12-LO Pathway in
The Development of Autoimmune Inflammatory
And Atherosclerotic Disorders in Humans

Increasing evidence suggests that cytokines such as
5 IL₁, IL₄ and IL₈ play a role in the development of
autoimmune, inflammatory and atherosclerotic disorders in
humans.

Description of Figures 14-20

Figure 14A illustrates the dose-dependent effect of
10 the cytokine interleukin-1 β on 12-LO mRNA expression in
porcine aortic smooth muscle cells (PVSMC). Confluent
PVSMC growth in normal glucose medium was serum depleted
for 24 hours by placing in medium + 0.2% BSA + 0.4% FCS.
This medium was then freshly replaced along with IL-1 β
15 and the cells incubated for a further 24 hours. At the
end of the incubation, total RNA was extracted from the
cells using RNA-STAT. This RNA was subjected to
reverse-transcriptase polymerase chain reaction (RT-PCR)
to detect and quantitate leukocyte-type 12-LO mRNA (333
20 bp PCR product, upper panel) using our well established
techniques. The expression of GAPDH mRNA 284 bp, lower
panel) was used as an internal control for PCR and for
quantitation. The figure clearly shows that IL-1 β
treatment leads to a dose-dependent increase in 12-LO
25 mRNA expression (333 bp PCR product) while there is not
much change in the internal control, GAPDH mRNA
expression.

Figure 14B illustrates the effect of the cytokine
IL-4 on 12-LO mRNA expression in PVSMC. The cells were
30 treated for 24 hours with IL-4 and 12-LO mRNA quantitated
as described in the legend to Figure 14A. It is clearly
seen that IL-4 also increases 12-LO mRNA expression
similar to IL-1 β .

-35-

Figure 14C illustrates the effect of the cytokine IL-8 on 12-LO mRNA expression in PVSMC. The cells were treated for 24 hours with IL-8 and 12-LO mRNA quantitated as described under legend 14A. The figure shows that 5 IL-8 treatment of PVSMC leads to dose-dependent increase in 12-LO mRNA expression while there is no change in the internal control, GAPDH expression.

Figure 15 illustrates the same RNA analyzed for the internal marker GAPDH.

10 Figure 16 illustrates the effect of IL-4 on leukocyte-type 12-LO protein expression in PVSMC.

Figure 17 illustrates the effect of IL-8 on leukocyte-type 12-LO protein expression in PVSMC.

15 Figure 18 illustrates the effect of IL-4 on 12-LO activity in PSMC.

Figure 19 illustrates the effect of IL-8 on 12-LO activity in PSMC.

Figure 20 reflects the upregulation of h1 12-LO by IL-1, IL-4 and IL-8.

20 In addition to this work in islets, applicants have now demonstrated that IL₁, IL₄ and IL₈ can increase the mRNA expression of leucocyte type 12-LO in porcine and human aortic smooth muscle cells. Furthermore, applicants have evidence that 12-LO protein expression is 25 similarly upregulated by these cytokines in porcine vascular smooth muscle. The cells were cultured in DME (normal glucose) and treated for 24 hours ± cytokines in medium containing 0.2% BSA and 0.4% serum. Intracellular 12-LO enzyme activity was measured by HPLC, leukocyte-type 12-LO protein expression by immunoblotting and 12-LO mRNA by a specific reverse transcriptase polymerase chain reaction (RT-PCR). All three cytokines (2.5 ng/ml) caused a marked increase in 12-LO enzyme activity 51, 43 and 36% increase in 12-HETE HPLC peak for IL-1, -4 and -8

respectively). Further, all three cytokines (1-5 ng/ml) each led to a potent dose-dependent increase (2-5 fold) in 12-LO mRNA expression (340 bp PCR product). Treatment with these cytokines (0.5-5 ng/ml) also led to an
5 increase (1.4 -2.5-fold) in 12-LO protein expression (72 kD). In addition, all three cytokines (2.5 ng/ml) could induce a significant increase in PVSMC DNA synthesis (1.280.08, 1.67±0.11 and 1.3±0.07 fold increase in ^3H thymidine incorporation with IL-1, -4, and -8
10 respectively, $p<0.01$).

Human vascular smooth muscle cells (HSMC) were also cultured in DME (normal glucose) and treated for 24 hours with IL₁, IL₄ and IL₈ in medium containing 0.2% BSA and 0.4% serum. Intracellular 12-LO enzyme activity in cell
15 sonicates was measured by HPLC, leukocyte-type 12-LO protein expression by immunoblotting and 12-LO mRNA by a specific reverse transcriptase polymerase chain reaction (RT-PCR). Treatment of HSMC in low serum medium for 24 hours with IL-1, IL-4 or IL-8 (5 ng/ml) resulted in 7-10
20 fold increases in 12-LO mRNA expression relative to untreated cells. RNA from the same experiments was also analyzed for human 12-LO expression by a specific RT-PCR. No 15-LO mRNA was seen either in the basal or after cytokine addition.

25 These results suggest that these inflammatory cytokines have mitogenic effects in VSMC and that they are potent positive regulators of the 12-lipoxygenase pathway. Thus enhanced 12-LO activity and expression in response to these cytokines may be a key mechanism for
30 cytokine-induced VSMC migration and proliferation observed in atherosclerosis. Figure 14 shows the effects of IL₁, IL₄ and IL₈ on 12-LO mRNA expression in PVSMC cultured in normal (5.5 mM) and elevated (25 mM) glucoside. Figure 15 represents the same RNA analyzed

-37-

for the internal marker gene GAPDH showing all lanes have similar amounts of internal standard RNA. Figures 16 and 17 show increases in 12-LO protein expression in PVSMC by IL₄ and IL₈ respectively and Figures 18 and 19 reveal HPLC tracings showing selective increases in 12-LO protein activity in PSMC treated with IL₄ and IL₈ respectively. Figure 20 shows evidence that IL₁, IL₄ and IL₈ can markedly upregulate leucocyte type 12-LO in human aortic SMC. In these same experiments, applicants were unable to demonstrate 15-LO expression in untreated or cytokine treated HSMC demonstrating the selective role of 12-LO as a potential mediator of cytokine action in vascular smooth muscle.

Role of 12-LO Pathway in The Pathogenesis of Type I and II Diabetes

Insulin dependent diabetes or type I diabetes is an autoimmune disease resulting in complete destruction of the insulin producing cells or beta cells in the pancreatic islet. Cytokines such as IL-1 β are likely to be involved in this autoimmune process.

It has been discovered that IL-1 β induces 12-LO protein and mRNA expression in RIN-M5F cells and 12-LO mRNA expression in rat islets. RIN-M5F cells treated for 16 hours with IL-1 β (25, 50 and 100 ng/L) showed a dose dependent two-fold increase in expression of a porcine leukocyte form of 12-LO demonstrated by Western blots. A concomitant increase in 12-LO mRNA expression was seen at this time point using a highly sensitive competitive PCR assay. These transcriptional and translational events were paralleled by increased 12-LO pathway activity measured by radioimmunoassay for 12-HETE. Additionally, an inhibitor of inducible nitric oxide synthase (iNOS), N-monomethyl arginine (NMMA), was unable to prevent the IL-1 β induced increase in 12-LO protein expression in RIN

-38-

M5F cells, supporting the hypothesis that a pathway independent of inducible nitric oxide (NO) is present. Separate experiments using purified Sprague-Dawley rat islets also showed increased expression of 12-LO mRNA and 5 enzyme activity.

In conclusion, 12-LO is a β -cell specific enzyme regulated at the transcriptional and translational level by cytokines like IL-1 β .

Description of Figures 21-24

10 Figure 21 reflects the increase in 12-LO mRNA expression in the pancreatic islets of increasingly diabetic rats.

15 Figure 22 indicates that 12-LO mRNA expression in diabetic ZDF rat skeletal muscle is higher than from non-diabetic ZDF rats. The ZDF rat model has been proposed as an excellent animal model of spontaneous NIDDM (non-insulin dependent diabetes mellitus).

Figure 23 presents data pertaining to rat-fibroblasts which overexpress the human insulin receptor.

20 Figure 24 reflects a major change in the HETE/PGI₂ ratio in various diabetic groups.

NIDDM is a complex genetic disorder associated with a reduced ability of insulin to induce glucose transport in muscle ("insulin resistance") and a relative 25 impairment of glucose-induced insulin secretion in pancreatic islets.

Consistent with another aspect of this invention, increased activity or expression of the 12-LO pathway is recognized as a common mediator of both of these 30 abnormalities, such that blockade of the 12-LO pathway may prevent development of NIDDM.

The rationale for this statement includes:

1. Highly relevant data which evidences the presence of the leukocyte type 12-LO in pancreatic islets

-39-

and skeletal muscle. The data in skeletal muscle is new and highly relevant. The available data in rat skeletal muscle and in human islet muscle RNA shows 12-LO expression using PCR analysis.

5 2. Evidence that 12-LO mRNA expression progressively increases in rat pancreatic islets from lean non-diabetic animals, to obese pre-diabetic and obese diabetic animals (see Figure 21).

10 3. Data that 12-LO products added exogenously to rat pancreatic islets can reduce glucose-induced insulin secretion (45).

15 4. In vivo data (see Table 2) that urinary 12-HETE levels are much higher in male diabetic obese ZDF rats (a model of NIDDM) compared to lean ZDF non-diabetic rats.

15 Interestingly, obese female ZDF rats which are phenotypically like pre-diabetic humans show intermediate levels of 12-HETE in urine.

Table 2

Urinary 12-HETE in ZDF Rats

	<u>pg/total urine vol.</u>
20 Diabetic Male Obese Ctrl	2022 ± 372
Non-diabetic Female Obese Ctrl	1007
Female Obese Mg2+	86
25 Non-diabetic Lean Male	--
Lean Female	--

5 5. Data which indicates that 12-LO mRNA expression in diabetic ZDF rat skeletal muscle is much higher than levels in skeletal muscle from non-diabetic ZDF rats (lane 11 vs lane 21 in Figure 22). Interestingly, 12-LO mRNA levels in skeletal muscle are also higher in obese female ZDF rats that are prone to get diabetes. In this figure, the 312 bp band is the 12-LO band while the 281

-40-

bp band is the 12-LO competitor. This data represents true competitive PCR analysis of 12-LO mRNA. Applicants also have data in the ZDF heart that suggests that 12-LO expression is also higher in diabetic cardiac tissue.

5 In addition to this work, 12-LO RNA and protein expression in two NIDDM models, ZDF (Zucker diabetic fatty) rats and GK (Goto Kyoto) rats have been evaluated. A specific quantitative polymerase chain reaction (PCR) assay was used to measure 12-LO mRNA expression and
10 Western blotting using an anti 12-LO peptide antibody was used to evaluate 12-LO protein expression. The GK rat model of NIDDM demonstrated an increased blood glucose concentration compared to age-matched Wistar controls (8.7 ± 0.7 vs 4.8 ± 0.2 mM, $p<0.01$). However, plasma
15 insulin and body weight were similar between the GK and Wistar rats. 12-LO mRNA expression was 4-fold greater in heart from GK rats compared to Wistar ($0.48 \pm 0.1 \times 10^5$ molecules per μg RNA in Wistar vs $1.9 \pm 0.4 \times 10^5$ in GK $p<0.02$). 12-LO mRNA expression in soleus muscle was over
20 5-fold greater in GK vs Wistar rats (0.6 ± 0.1 Wistar vs 3.1 ± 0.76 GK). The ZDF obese rats demonstrated an increase in blood glucose concentration and weight compared to the ZDF lean controls (558 ± 75 vs 170 ± 5 mg/dl and 390 ± 7 vs 343 ± 7 gram respectively). 12-LO
25 mRNA was analyzed in the heart, red and white quadriceps muscle in the diabetic and lean ZDF rats. 12-LO mRNA expression was increased by 4-7 fold in the diabetic obese ZDF rats compared to the lean ZDF controls. 12-LO protein expression was similarly increased in heart
30 tissue (5-fold) in the diabetic ZDF vs the lean ZDF controls. These data reflect that muscle 12-LO expression is markedly increased in both lean and obese rat models of NIDDM.

-41-

6. Data which indicates that 12-HETE levels in L₆ muscle cells are increased in the presence of glucose. L₆ muscle cells are skeletal muscle cells from rats which have been used to investigate the mechanisms of insulin action. When L₆ muscle cells are incubated in xylose (5.5, mM), they are much more responsive to insulin when compared to cells in regular glucose (5.5 mM) or high glucose (25 mM). Table 3 below demonstrates higher levels of 12-HETE release in the media (pg/ml) or in the cells (pg/total cells) in regular glucose (Rg) or high glucose (HG) conditions. Thus, elevated 12-Lipoxygenase products, such as 12-HETE, appear to play an important role in reduced insulin metabolic actions caused by high glucose.

15

Table 3Effect of Glucose on 12-HETE in L₆ Muscle Cells

<u>Cells</u>	<u>Condition</u>		
L ₆	Xylose	Rg	Hg
pg/ml (n=2)	53.2	101.8	110.3
20 pg/total cells (n=2)	398	472	620

7. Baicalein, a selective 12-LO inhibitor, can prevent glucose-induced insulin resistance. To perform these studies, applicants cultured rat-1-fibroblasts that have been engineered to contain the human insulin receptor for ten days in high glucose (25 mM). For the last 24 hours, the cells were cultured with 10⁻⁶M baicalein. The marked bands represent the phosphorylated beta sub-unit of the human insulin receptor (Figure 23). As the band becomes lighter, it represents reduced insulin action. Lane 1 represents the insulin receptor phosphorylation in normal glucose (5.5 mM) vs the reduced insulin action in lane 5 (25 mM glucose). Lane 6 represents the insulin receptor phosphorylation in 25 mM

-42-

glucose when 12-LO pathway was blocked with baicalein showing restoration of insulin receptor phosphorylation.

In addition to this work, applicants have discovered that 12-HETE directly inhibits insulin-induced receptor phosphorylation. As shown in Figure 27, a clear increase in phosphorylation of the 97 kD beta subunit of the insulin receptor occurs when insulin is present. This is demonstrated by a darker band at 97 kD in lane 4 (insulin-treated) vs Lane 1 (control, non-insulin-treated). 12-HETE (10^{-7} M concentration) did not directly alter basal insulin receptor phosphorylation (lane 2). In contrast, 12-HETE markedly reduced insulin-induced receptor phosphorylation of the beta subunit of the human insulin receptor. This is demonstrated by a reduced band intensity in lane 5 (12-HETE 10^{-7} M) vs. Lane 4 (no 12-HETE addition).

Since insulin receptor phosphorylation is one of the early important steps in insulin action, these results suggest that products of the 12-LO pathway can lead to reduced insulin action. This data suggests that increased expression or activity of the 12-LO pathway appears to play a key role in the insulin resistance in non-insulin dependent forms of diabetes.

8. Data which indicates that glucosamine, a proposed major mediator of glucose toxicity in terms of reduced insulin action and vascular disease, increases 12-LO product formation in smooth muscle cells. The role of glucosamine in leading to insulin resistance has recently been demonstrated in intact animals (Baron et al., J. Clin. Invest., 96:2792-2801 (1995)) and in insulin responsive tissues in vitro (e.g., muscle -- Robinson et al., Diabetes, 42:1333-46 (1993); and fat -- Marshall et al., J. Biol. Chem., 266:4706-4712 (1991)). Furthermore, glucosamine is thought to be a major

-43-

mediator of glucose-induced vascular disease (Daniels et al., Mol. Endocrinol., 7:1041-1048 (1993)). While not wishing to be bound by a particular theory, it is believed that glucosamine impairs insulin-induced glucose uptake by blocking the normal action of Glut 4, the major glucose transporter linked to insulin ability to transport glucose.

Porcine vascular smooth muscles cells (PVSMC) were cultured in the presence of glucosamine (7.5 mM) for 24 hours. New media was then added with glucosamine (7.5 mM) for 25 minutes. The cells and media above the cells were collected and 12-HETE was measured using RIA. A very large increase in 12-HETE release into the media in cells cultured in glucosamine compared to those in normal glucose (6.48 ± 1.2 pg/ml 12-HETE release in normal glucose vs. 20.6 ± 3.6 pg/ml released in glucosamine n=4) was observed. Furthermore, cell associated 12-HETE was higher in glucosamine treated cells (735.9 ± 67 pg/cell incubate normal glucose vs. 1225 ± 112 pg in glucosamine). These data suggest that 12-LO products such as 12-HETE may be important factors leading to insulin resistance.

9. Data which indicates that high fat feeding simultaneously leads to impaired insulin action and induction of 12-LO protein expression in muscle. The mouse model used was a transgenic mouse over expressing the Glut 4 transporter (Pfizer Pharmaceuticals). As can be seen in Figure 28, high fat feeding clearly led to impaired glucose tolerance, which is a clear indication that the animals were insulin resistant. Figure 28a shows a higher glucose level at every point on the oral glucose test curve in the fat fed mice than in the control. The bar graph of Figure 28b demonstrates a

-44-

significantly greater area under the glucose tolerance curve in the high fat fed group than in the control.

In four of the animals on the high fat diet, 12-LO protein expression in cardiac muscle was evaluated and
 5 compared to the levels in animals on the control diet.
 12-LO protein expression was measured using 12-LO peptide antibody and Western blotting. The summary of the data is shown in Table 4 below. The striking results show much higher levels of 12-LO protein (using densitometric
 10 analysis of blots) in animals on the high fat diet. These in vivo results suggest that increased 12-LO expression or activity plays a key role in leading to insulin resistance.

Table 4

15 Densitometry Result Comparisons of
 12-LO Protein Expression in Heart Muscle Western Blot

Mann-Whitney Test

Mann-Whitney U-statistic = 0.000
 U' = 16.000
 20 Sum of ranks in Control Male = 10.000
 Sum of ranks in Fat Male = 26.000

The two-tailed P value is 0.0286, considered significant.

		Control Diet	High Fat Fed Diet
	Parameter:	Control Male	Fat Male
	Mean:	2.925	12.897
25	# of points:	4	4
	Std deviation:	1.041	14.636
	Std error:	0.5203	7.318
	Minimum:	1.890	5.390
30	Maximum:	4.370	34.850
	Median:	2.720	5.675
	Lower 95% CI:	1.269	-10.388
	Upper 95% CI:	4.581	36.183

-45-

10. Data which indicates that high magnesium (Mg) feeding markedly reduces 12-LO gene expression and 12-HETE levels. Mg deficiency has been associated with experimental and human insulin resistance. Moreover, 5 increased dietary Mg has been associated with reduced development of diabetes in ZDF rats as well as in humans, and Mg supplementation can improve insulin response and actions in humans with NIDDM.

It has now been discovered that high Mg feeding 10 markedly reduces 12-LO gene expression and 12-HETE levels. High Mg diets (Purina 5008 diet containing 1% Mg) were fed to one group of ZDF obese (diabetic fatty) male rats while control diets (Purina 5008 plus 0.2% Mg) were fed to another group. As can be seen in Table 5, 15 the high Mg feeding group possessed significantly lower urinary 12-HETE concentrations as measured by RIA (methods described in J. Clin. Endocrin. Metab., 67:584-591 (1988) and J. Clin. Invest., 80:1763-1769 (1987)) than the control group. High Mg feeding also reduced 12- 20 LO mRNA expression in muscle from diabetic ZDF rats.

Table 5

**Urinary 12-HETE Excretion
Rate in ZDF Rat Models**

ZDF RAT	12-HETE (pg/min)
ZDF lean (n=4)	^a 0.4 ± 0.07
ZDF obese (n=6)	6.12 ± 1.2
ZDF obese (n=6) with h.Mg diet	^b 3.72 ± 0.5

Values are mean ± SE. n is the number of rats.
30 Values in ZDF lean group and ZDF obese with high magnesium diet group are different from ZDF obese group at ^ap<0.001 and ^bp<0.05 respectively.

-46-

11. Human data shows increased urinary levels of 12-HETE in people with NIDDM. Levels of 12-HETE are particularly high in diabetics showing evidence of proteinuria. These results suggest that 12-LO activation
5 may be involved in renal disease in diabetes.

Vascular tissue from diabetic animals and man metabolize arachidonic acid differently from normals. PGI₂ is a vasodilator, antithrombotic, and renin secretagogue while 12-hydroxyeicosatetraenoic acid (12-HETE) is proinflammatory and inhibits cyclooxygenase (CO). Applicants earlier reported a prostacyclin (PGI₂) deficiency in diabetics with hyporeinemic hypoaldosteronism (HH) (46). Applicants explored the production of the CO product, PGI₂, and the lipoxygenase 15 (LO) product, 12-HETE in NIDDM patients with normal renal function (NR), those with microalbuminuria (MiA), macroalbuminuria (MaA) and HH patients. PGI₂ (6 keto PGF¹) and 12-HETE were measured in urine by HPLC followed by RIA using published methods. Results are:

		<u>PGI₂</u> (ng/gm Creat)	<u>12-HETE</u> (ng/gm Creat)	<u>Ratio</u>
20	Controls (N=17)	64±16	43±9	0.7±0.3
	Diabetics (NR) (N=8)	64±9	122±34*	2.0±0.5
	Diabetics (MiA) (N=14)	75±10	226±60*	3.8±1.3
25	Diabetics (MaA) (N=9)	48±7**	352±152*	8.1±5.4
	Diabetics (HH) (N=5)	39±5	240±35*†	6.8±2.4

† From previously stored samples

* p<0.01 vs controls

** p<0.05 vs diabetics

30 This data suggests that (1) an increase in the 12-LO product 12-HETE is observed in all NIDDM which progresses with renal disease; (2) diabetic renal disease with albuminuria is associated with suppression of PGI₂ production; and (3) HH is a disorder of PGI₂ suppression 35 and 12-HETE excess.

-47-

Applicants further study has measured urinary (renal vascular) production of both PGI₂ and 12-HETE in patients with varying degrees of diabetic renal involvement.

In the group of NIDDM patients with normal renal function based on creatinine clearance and urinary albumin measurements, PGI₂ excretion was not different from normal controls. The group with microalbuminuria were divided into those with hypertension and normotensive. However, no difference in PGI₂ excretion was noted. Nevertheless the microalbuminuria group had significantly lower PGI₂ excretion rates. The patients with macroalbuminuria and reduced creatinine clearance similarly had reduced PGI₂ excretion. PGI₂ excretion rates were reduced in the macroalbuminuria and HH group.

12-HETE values were markedly increased in NIDDM patients with or without microalbuminuria compared with normal controls. 12-HETE excretion values were also significantly increased in the macroalbuminuria group as well as in the HH group.

Low dose calcium infusions have been previously shown to increase PGI₂, probably via activation of tissue phospholipases. When a three hour infusion of calcium gluconate was administered to normal subjects, there was a highly significant increase in both PGI₂ and 12-HETE.

However, when administered to NIDDM patients with microalbuminuria, there was no increase in PGI₂ but a further stimulation of the already increased 12-HETE values. This supports the concept that a defect in prostacyclin formation exists in NIDDM.

12-HETE/PGI₂ ratios were calculated as an additional approach to define whether in NIDDM there is an alteration in the LO/CO pathways. As shown in Figure 24, there is a major change in the HETE/PGI₂ ratio in all diabetic groups. The mean value is significantly

increased in NIDDM patients with normal renal function and is further altered in patients with macroalbuminuria and HH patients. However, these differences were not significantly different between the NIDDM groups due to 5 the variability within each group.

Applicants data appears to exclude renal function per se, GFR or hypertension as a cause of the deranged eicosanoid excretion values. While the origin of PGI₂ and 12-HETE in urine has not been fully settled, studies 10 using extrarenal CO inhibitors and lack of excretion of tracer PGI₂ and 12/15-HETE following systemic injection, suggests that the kidney is the major source of these compounds in urine (47-49). HETEs can be generated in vascular tissue as well as from inflammatory cells. 15 (50-51). However, there is no evidence for macrophage/leukocytes infiltration into the kidney in NIDDM with only incipient glomerular and vascular disease.

In agreement with in vitro and animal model studies 20 cited earlier, applicants results suggest that early in diabetes mellitus, there is fixed prostacyclin production which falls to lower values with diabetic renal vascular/glomerular disease. This occurs in a state where the LO product 12-HETE is increased early in 25 diabetes mellitus prior to development of microalbuminuria. These observations could be of considerable importance in the etiology of diabetic vascular disease since the HETEs are mitogenic proinflammatory, vasoconstrictive, and stimulate 30 angiogenesis (52-53). With respect to the HH syndrome, applicants new data suggests that increased HETE production may be an early abnormality in suppressing PGI₂ formation and renin biosynthesis and secretion. The etiologic event in diabetes explaining vascular disease

-49-

is not known. However, recent studies suggest that hyperglycemia per se has a number of metabolic consequences including enhanced eicosanoid generation via protein kinase C and activation of calcium dependent phospholipases, major mediators of AA release (54).

5 In summary, whether cause or effect, very early involvement of the kidney in diabetes is associated with fixed or suppressed production of prostacyclin, with increase in the vasculotoxic lipoxygenase product 12-HETE. This conclusion is now suggested by both in vitro studies and in vivo studies in man. This suggests pharmacologic intervention early in the diabetic state to 10 block this derangement.

15 Role of 12-Lipoxygenase Products in Glucose-Induced Monocyte Binding to Human Aortic Endothelial Cells

The rate of atherosclerosis is accelerated in humans with diabetes mellitus (DM). Applicants recently published evidence that high glucose (HG) exposure of 20 human aortic endothelial cells (HAEC) selectively increases monocyte (MO) but not neutrophil binding (56). HG exposure to EC can increase arachidonic acid (AA) release and lipoxygenase (LO) production formation. In the current study, applicants evaluated the role of 12- and 15-LO products in MO binding to HAEC. Culture of HAEC in HG (25 mM) for two passages increased MO binding compared to cells maintained in 5.5 mM glucose (239 ± 30 cells/field HG vs 111 ± 7 , $p < 0.01$). Phenidone (10^{-6} M), an inhibitor of the 12-LO pathway (50 percent inhibition of 25 HG-induced binding, $p < 0.05$). HG culture of HAEC significantly increased both 12- and 15-hydroxyeicosatrienoic acids (HETEs) using applicants HPLC and RIA methods. 12(S)-HETE added to HAEC cultured in 5.5 mM glucose increased MO binding (66 ± 6 cells/field 30

-50-

control vs 114 ± 4 12-HETE $10^{-10}M$, $p < 0.01$). Another novel 12-LO product 12(R)-Hydroxyeicosatrienoic acid was even more potent showing effects on MO binding at 10^{-11} and $10^{-12}M$. In contrast, 15(S)-HETE added at concentrations 5 ranging from 10^{-6} to $10^{-12}M$ did not stimulate MO binding to HAEC. In summary, (1) elevated glucose increases MO binding to HAEC and this effect can be reduced by blockade of the LO pathway; (2) 12 but not 15-LO products, can increase MO binding. Since a leucocyte 10 type 12-LO is expressed in HAEC, these results support the role of 12-LO activation in glucose-induced MO binding to human endothelium.

Applicants have also demonstrated that high fat "cafeteria" diets increase leukocyte 12-LO in rat hearts 15 and that diabetic (GK) rats have a higher 12-LO in heart compared to normal (Wistar) animals (see Figures 25 and 26).

DIAGNOSTIC ASSAYS

Application PCT/US94/00089 reports that antibodies 20 would circulate in patients at risk for developing disease states for which h1 12-LO or its pathway products such as HETE or 12-HPETE are the etiological agent. Accordingly, another aspect of this invention includes assays, e.g., of the ELISA type in which h1 12-LO 25 protein, or a related material such as HETE is utilized as an immunogen. Such tests are useful to diagnose any of the disease states mediated by the activation or expression of h1 12-LO.

-51-

BIBLIOGRAPHY

1. Geisterfer, A.A., et al., Circ. Res. (1988) 62:749-756.
- 5 2. Izumi, T., et al., Proc. Natl. Acad. Sci. USA (1990) 87:7477-7481.
3. Gu, J., et al., Endocrinology (1994) 143:70-77.
4. Samuelsson, B., Science (1987) 237:1171-1176.
5. Sparrow, C.P., et al., J. Lipid Res. (1988) 29:745-753.
- 10 6. Steinberg, D., New Eng. J. Med. (1989) 320:915-924.
7. Berk, B.C., Hypertension (1989) 13:305-314.
8. Schwartz, S.M., Physiol. Rev. (1990) 70:1177-1209.
9. Nakao, J., et al., Atherosclerosis (1982) 44:339-342.
- 15 10. Natarajan, R., et al., J. Clin. Endocrinol. Metab. (1988) 67:584-591.
11. Nadler, J.L., et al., J. Clin. Invest. (1987) 80:1763-1769.
12. Natarajan, R., et al., Endocrinology (1992) 131:1174-1180.
- 20 13. Funk, C.D., et al., Proc. Natl. Acad. Sci. USA (1990) 87:5638-5642.
14. Yoshimoto, T., et al., Proc. Natl. Acad. Sci. USA (1990) 87:2142-2146.
- 25 15. DeMarzo, N., et al., Am. J. Physiol. (1992) 262:L198-L207.
16. Rapoport, S.M., et al., Eur. J. Biochem. (1979) 96:545-561.
17. Sigal, E., et al., J. Biol. Chem. (1988) 263:5328-5332.
- 30 18. Nadel, J.A., et al., J. Clin. Invest. (1991) 87:1139-1145.
19. Pitas, R.E., Arteriosclerosis (1981) 1:177-185.

-52-

20. Gown, A.M., et al., Am. J. Pathol. (1986) 125:191-207.
21. Fogelman, A.M., et al., J. Lipid Res. (1988) 29:1243-1247.
- 5 22. Sigal, E., et al., Biochem. Biophys. Res. Commun. (1988) 157:457-464.
23. Tso, J.Y., et al., Nucleic Acids Res. (1985) 13:2485-2502.
24. Laemmli, N.K., Nature, (1970) 227:680-685.
- 10 25. Towbin, H., et al., Proc. Natl. Acad. Sci. USA (1979) 76:4350-4354.
26. Esteban, J.M., et al., Modern Pathology (1990) 3:192-197.
27. Lopez, S., et al., Biochem. Biophys. Acta (1993) 1170:17-24.
- 15 28. Conrad, D.J., et al., Proc. Natl. Acad. Sci. USA (1992) 89:217-221.
29. Stern, N., et al., Am. J. Physiol. (1989) 257:H434-H443.
- 20 30. Funk, C.D., et al., J. Biol. Chem. (1985) 260:7481-7488.
31. Natarajan, R., et al., Biochem. Biophys. Res. Commun. (1992) 187:552-560.
32. Kato, H., et al., J. Hypertens. (1991) 9:17-22.
- 25 33. Daemaen, MJAP, et al., Circ. Res. (1991) 68:450-456.
34. Osterrieder, et al., Hypertension (1991) 18 (Supp. II):II-60-II-64.
35. Natarajan, R., et al., Hypertension (1994) 23 (Supp. I):I142-I147.
- 30 36. Haliday, E.M., Embo. J. (1991) 10:109-115.
37. Yu, C.L., Mol. Cell Biol. (1990) 10:6683-6689.
38. Rao, G.N., et al., Oncogene (1993) 8:2759-2764.
39. Ylä-Herttuala, S., et al., Proc. Natl. Acad. Sci. USA (1990) 87:6959-6963.

-53-

40. Ylä-Herttuala, S., et al., J. Clin. Invest. (1991) 87:1146-1152.
41. Parthasarathy, S., J. Clin. Invest. (1992) 89:1618-1621.
- 5 42. Mathur, S., et al., Biochim. Biophys. Acta (1985) 837:13-19.
43. Reinard, O., et al., Biochem. Biophys. Res. Comm. (1989) 161:883-891.
44. Hajjar, D., et al., J. Biol. Chem. (1987) 262:6976-10 6981.
45. Nathan, M., Pek, B. Lipoxygenase-generated iicosanoids inhibit glucose-induced insulin release from rat islets. Prost leukotrienes and essential fatty acids. (1990) 40:21-25.
- 15 46. New Eng. J. Med., (1986) 314:1015.
47. Fitzgerald, G., et al., Circ. Res. (1983) 67:1174-7.
48. Ciabattoni, G., et al., N. Eng. J. Med. (1984) 310:279-83.
49. Clouet, P., et al., Prostaglandin (1991) 42:39-45.
- 20 50. Greenwald, J.E., et al., Nature (1979) 281:588-89.
51. Larrue, J., et al., Biochem. Biophys. Res. Commun. (1983) 112:242-49.
52. Setty, B., et al., J. Biol. Chem. JBC (1987) 262:17613-22.
- 25 53. Yoshimoto, T., Proc. Natl. Acad. Sci. USA (1990) 87:2142-46.
54. DeRubertis, F., Diabetes (1994) 43:1-8.
55. Alanko, J., et al., Biochem. Pharm. (1994) 10:1979).
56. Diabetes 43:1103-1107 (1994).

-54-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Jerry L. Nadler
Rama Natarajan
- 5 (ii) TITLE OF INVENTION: Human Leukocyte 12-Lipoxygenase and Its Role in the Pathogenesis of Disease States
- (iii) NUMBER OF SEQUENCES: 12
- (iv) CORRESPONDENCE ADDRESS:
- 10 (A) ADDRESSEE: City of Hope
- (B) STREET: 1500 East Duarte Road
- (C) CITY: Duarte
- (D) STATE: California
- (E) COUNTRY: United States of America
- 15 (F) ZIP: 91010-0269
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: 3M Double Density 5 1/4" diskette
- (B) COMPUTER: Wang PC
- 20 (C) OPERATING SYSTEM: MS DOS Version 3.20
- (D) SOFTWARE: Wordperfect
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:
- (B) FILING DATE: 04 May 1995
- 25 (C) CLASSIFICATION: Unknown
- (vii) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER: PCT/US94/00089

-55-

(B) FILING DATE: 4 January 1994

(C) APPLICATION NUMBER: 07/936,660

(D) FILING DATE: 28 August 1992

(viii) ATTORNEY/AGENT INFORMATION:

5 (A) NAME: Irons, Edward S.

(B) REGISTRATION NUMBER: 16,541

(C) REFERENCE/DOCKET NUMBER: None

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (202) 783-6040

10 (B) TELEFAX: (202) 783-6031

(C) TELEX: None

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

15 (B) TYPE: Nucleotide

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

AACTCAAGGT GGAAC TACCG GAG

23

20 (2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: Nucleotide

(C) STRANDEDNESS: Single

25 (D) TOPOLOGY: Linear

-56-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

ATATAGTITG GCCCCAGCCA TATT

24

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 20

(B) TYPE: Nucleotide

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

10 AGGCTCAGGA CGCCGTTGCC

20

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleotide

15 (C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TTCAGTGTAG ACGTGTCGGA G

21

(2) INFORMATION FOR SEQ ID NO: 5:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: Nucleotide

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

- 57 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

ATGTATGCCG GTGCTGGCTA TATT 25

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 22
(B) TYPE: Nucleotide
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

10 TCAGGATGCG GTCGCCCTCC AC 22

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21
(B) TYPE: Nucleotide
15 (C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CCCATCACCA TCTTCCAGGA G 21

(2) INFORMATION FOR SEQ ID NO: 8:

- 20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21
(B) TYPE: Nucleotide
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

-58-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GTTCTCATGG ATGACCTTGG C 21

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 21

(B) TYPE: Nucleotide

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

10 CTAAGCAGTT GGTGGTGCAG G 21

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleotide

15 (C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GATGATCTAC CTCCAAATAT G 21

(2) INFORMATION FOR SEQ ID NO: 11:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleotide

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

-59-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

CTGGCCCCAG AAGATCTGAT C 21

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 22

(B) TYPE: Nucleotide

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

10 GTTTGAGGGC CATCTCCAGA GC 22

-60-

CLAIMS:

1. Isolated and purified human 12-lipoxygenase from human tissue, said isolated and purified human 12-lipoxygenase being distinct from that found in human platelets and distinct from human 15-lipoxygenase.

2. The isolated and purified human 12-lipoxygenase of claim 1, wherein said 12-lipoxygenase is from human vascular smooth muscle cells, adrenal cells, endothelial cells or monocytes.

3. A method for diagnosing a disease state in a patient in which the 12-lipoxygenase of claims 1-2 or 12-HETE is an etiological agent which comprises:

5 (i) obtaining a physiological specimen from said patient; and

(ii) determining whether the etiological agent or antibodies to said etiological agent are present in said specimen.

4. The method of claim 3 in which said disease state is an inflammatory or autoimmune condition atherosclerosis, cancer growth, cancer metastasis, dysfunctional secretion of insulin in non-insulin dependent diabetics, glucose-induced oxidative stress or the development of end-organ dysfunction or damage.

5 5. The method of claim 4, wherein said disease state is atherosclerotic vascular disease, human breast cancer, or Type II diabetes.

6. A method for treating a patient suffering from a disease state in which hl 12-lipoxygenase or 12-HETE is an etiological agent which comprises administering to said human patient an hl 12-lipoxygenase inhibitor in an amount effective to retard or inhibit expression of said hl 12-lipoxygenase.

7. The method of claim 6, wherein said disease state is Type II diabetes or breast cancer.

8. The method of claim 6, wherein said disease state is non-insulin dependent diabetes mellitus and the human 12-lipoxygenase inhibitor is administered in an amount therapeutically effective to enhance the ability 5 of insulin to induce glucose transport in muscle and the secretion of insulin in pancreatic islets.

9. The method of claim 6, in which said inhibitor is NDGA, CDC, panaxynol, baicalein, pioglitazone, aminoguanidine or a ribozyme which cleaves hl 12-lipoxygenase mRNA.

10. A method for inhibiting or reducing vascular endothelial growth factor production in a human patient which comprises administering to said patient an hl 12-lipoxygenase inhibitor in an amount effective to retard 5 or inhibit the expression of hl 12-lipoxygenase.

11. A method for the treatment of a human patient suffering from a cytokine mediated autoimmune, inflammatory or atherosclerotic disorder which comprises administering to said patient a human 12-lipoxygenase 5 inhibitor in an amount therapeutically effective to mediate the action of said cytokine on human vascular smooth muscle.

12. The method of claim 11 in which said cytokine is interleukin 1, interleukin 4 or interleukin 8.

13. A method for reducing monocyte binding to human endothelial cells which comprises administering to a patient in need thereof an inhibitor of human 12-lipoxygenase in a therapeutically effective amount.

14. The method of claims 10, 11, 12 or 13, wherein said inhibitor is NDGA, CDC, panaxynol, baicalein, pioglitazone, aminoguanidine or a ribozyme which cleaves hl 12-lipoxygenase mRNA.

15. A method for generating lipid mediators which activate signal transduction pathways associated with

inflammatory and autoimmune conditions, atherosclerosis, cancer growth and metastasis, said lipid mediators being
5 hydroperoxides, kinases, mitogen activated kinases, transcription factors, and oncogenes which method comprises administering to a mammal in need thereof a therapeutically effective amount of arachidonic or linoleic acid, wherein said human 12-lipoxygenase
10 utilizes said acid to generate such a lipid mediator.

16. The method of claim 15 in which said lipid mediator is a hydroperoxide, a mitogen activated kinase or NFkB.

17. A method for increasing the activity and expression of human 12-lipoxygenase which comprises administering to a human patient a therapeutically effective amount of an inflammatory cytokine, a growth factor or angiotensin II.
5

18. The method of claim 17 in which said inflammatory cytokine is interleukin-1.

19. The method of claim 17 in which said growth factor is platelet derived growth factor.

20. A method for increasing the activity and expression of 12-lipoxygenase mRNA and protein in human aortic smooth muscle cells which comprises treatment of said cells with angiotensin II in an amount effective to increase said activity and expression.
5

21. A method for the reduction of angiotensin II related cardiovascular disease which comprises administration to a patient in need thereof a therapeutically effective amount of a drug effective to
5 blockade the human 12-LO pathway.

22. A method for inhibiting the proliferation of breast cancer tissue in a human patient which comprises administering to said patient a therapeutically effective

-63-

amount of a drug which inhibits human 12-LO expression or
5 activation.

23. The method of claim 22 in which said human 12-lipoxygenase inhibitor is NDGA, CDC, panaxynol, baicalein, pioglitazone, aminoguanidine or a ribozyme which cleaves hl 12-lipoxygenase mRNA.

24. The method of claim 22 in which the breast cancer cell growth and development is basal, epidermal growth factor-induced or estrogen induced.

25. A method for mediating breast cancer cell growth and development which comprises administering to a patient in need thereof a therapeutically effective amount of a human 12-lipoxygenase pathway inhibitor.

26. The method of claim 25 in which said human 12-lipoxygenase inhibitor is NDGA, CDC, panaxynol, baicalein, pioglitazone, aminoguanidine or a ribozyme which cleaves hl 12-lipoxygenase mRNA.

27. The method of claim 25 in which the breast cancer cell growth and development is basal, epidermal growth factor-induced or estrogen induced.

28. A method for monitoring cytokine induced vascular smooth muscle cell migration and proliferation observed in an atherosclerosis which comprises measuring the change in human 12-lipoxygenase mRNA or protein
5 expression by said cells upon treatment with a cytokine wherein an increase in said expression is indicative of said cell migration and proliferation.

29. A method for treating a patient having a disease state in which 12-HETE is an etiological agent which comprises decreasing mitogenic activity in said patient.

30. The method of claim 29, wherein the decrease in mitogenic activity results from reducing ERK, JAK and/or JNK activity in said patient.

-64-

31. The method of claim 30, wherein JNK activity is reduced by decreasing PAK activity.

32. The method of claim 29, wherein the mitogenic activity is decreased by administering a therapeutically effective amount of a 12-LO inhibitor to the patient sufficient to decrease mitogenic activity.

33. The method of claim 29, wherein the disease state is Type II diabetes or breast cancer.



34. A method for treating a patient having a disease state in which VEGF is an etiological agent which comprises decreasing the amount of VEGF in said patient.

35. The method of claim 34, wherein the disease state is proliferative diabetic retinopathy or accelerated vascular disease associated with diabetes.

36. The method of claim 34, wherein the amount of VEGF is decreased by administering to the patient a therapeutically effective amount of a 12-LO inhibitor sufficient to decrease VEGF in the patient.

37. A method for increasing insulin receptor phosphorylation in patients having Type II diabetes which comprises administering to the patient a therapeutically effective amount of a 12-LO inhibitor sufficient to inhibit 12-LO pathway products from inhibiting insulin receptor phosphorylation.

38. A method for reducing 12-LO gene expression and 12-HETE levels in a patient which comprises administering to the patient a therapeutically effective amount of Mg.

FIG. 1A**FIG. 1B**

HSMC
HAEc
Monocyte
12-L_O Standard

FIG. 2

2 / 23




FIG. 3A




FIG. 3B




FIG. 4B



FIG. 4A

4 / 23




FIG. 5A




FIG. 5B

WO 96/34943

PCT/US96/06328

5 / 23




FIG. 6A



FIG. 6B

WO 96/34943

PCT/US96/06328

6 / 23



FIG. 7A





FIG. 7B

SUBSTITUTE SHEET (RULE 26)

WO 96/34943

PCT/US96/06328

7 / 23



-42 kD

FIG. 8



-42 kD

FIG. 9




FIG. 10

9 / 23




FIG. 11




FIG. 12

10 / 23




FIG. 13




FIG. 14A

11 / 23




FIG. 14B




FIG. 14C




FIG. 15




FIG. 16

FIG. 17




FIG. 18

15 / 23




FIG. 19




FIG. 20




FIG. 21




FIG. 22

18 / 23




FIG. 23






FIG. 26

19 / 23

**FIG. 24****FIG. 25**






FIG. 27

21 / 23



- HIGH FAT FED ANIMALS
- CONTROL DIET

FIG. 28A**FIG. 28B**

22 / 23




FIG. 29




FIG. 30

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/06328

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N9/02 C12Q1/26 A61K31/00 A61K31/155 A61K31/35 A61K31/44 A61K31/20 A61K38/20 A61K38/18 A61K33/10										
According to International Patent Classification (IPC) or to both national classification and IPC										
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C12Q A61K										
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched										
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)										
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1"> <thead> <tr> <th>Category *</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X</td> <td> WO,A,94 05777 (CITY OF HOPE) 17 March 1994 cited in the application see page 1, paragraph 4 - page 3, paragraph 2 see page 6, paragraph 3 - page 7, paragraph 3 see page 12, paragraph 3 - page 15, paragraph 1 see page 17, paragraph 3 - page 20, paragraph 1 --- -/-/ </td> <td>1-11,13, 14,17, 20-37</td> </tr> </tbody> </table>					Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	WO,A,94 05777 (CITY OF HOPE) 17 March 1994 cited in the application see page 1, paragraph 4 - page 3, paragraph 2 see page 6, paragraph 3 - page 7, paragraph 3 see page 12, paragraph 3 - page 15, paragraph 1 see page 17, paragraph 3 - page 20, paragraph 1 --- -/-/	1-11,13, 14,17, 20-37
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.								
X	WO,A,94 05777 (CITY OF HOPE) 17 March 1994 cited in the application see page 1, paragraph 4 - page 3, paragraph 2 see page 6, paragraph 3 - page 7, paragraph 3 see page 12, paragraph 3 - page 15, paragraph 1 see page 17, paragraph 3 - page 20, paragraph 1 --- -/-/	1-11,13, 14,17, 20-37								
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.								
* Special categories of cited documents : 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed										
Date of the actual completion of the international search 18 September 1996		Date of mailing of the international search report 27.09.96								
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016		Authorized officer Montero Lopez, B								

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/06328

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, June 1993, WASHINGTON US, pages 4947-4951, XP002013548 RAMA NATARAJAN ET AL.: "Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells" see abstract see page 4947, right-hand column, paragraph 1 - paragraph 2 see page 4949, left-hand column, paragraph 1 - page 4951, right-hand column, paragraph 1</p> <p>---</p> <p>ENDOCRINOLOGY, vol. 134, no. 1, January 1994, pages 70-77, XP000601237 JIA-LI GU ET AL.: "Evidence that a leukocyte type of 12-lipoxygenase is expressed and regulated by AngiotensinII in human adrenal glomerulosa cells" see abstract see page 72, right-hand column, paragraph 2 - page 75, right-hand column, paragraph 1 see page 75, right-hand column, paragraph 3 - page 76, right-hand column, paragraph 4</p> <p>---</p> <p>WO,A,95 18609 (CITY OF HOPE) 13 July 1995 cited in the application</p> <p>see page 4, paragraph 2 - paragraph 4 see page 18, paragraph 1 - page 23, paragraph 1 see page 25, paragraph 2 - page 26, paragraph 1 see page 28, paragraph 1 - page 30, paragraph 2 see page 37, paragraph 3 - page 44, paragraph 2 see page 47, paragraph 3 - page 51, paragraph 1; examples</p> <p>---</p> <p>-/-</p>	3-5,11, 13-15, 17, 20-23, 25,26, 28,29,33
X		1,2,17, 20,21
P,X		1-11,13, 14,17, 20-37

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/06328

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>ENDOCRINOLOGY, vol. 136, no. 12, 1 December 1995, pages 5736-5744, XP000600977 DAVID BLEICH ET AL.: "Interleukin-1beta regulates the expression of a leukocyte type of 12-lipoxygenase in rat islets and RIN m5F cells" see abstract see page 5739, left-hand column, paragraph 3 - right-hand column, paragraph 3 see page 5740, left-hand column, paragraph 1 - page 5743, left-hand column, paragraph 2</p> <p>-----</p>	1,2,17, 18,28

1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/06328

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Please see Further Information sheet enclosed.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

Remark : Although claims 3-19, 21-27, 29-38 and, partially 20, as far as concerning an in-vivo method, are directed to a method of treatment of (diagnostic method practised on) the human/animal -body the search has been carried out and based on the alleged effects of the compositions.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No	
PCT, US 96/06328	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9405777	17-03-94	AU-A-	4840393	29-03-94
		CA-A-	2077461	01-03-94
		EP-A-	0621895	02-11-94
		EP-A-	0696193	14-02-96
		JP-T-	7500254	12-01-95
		WO-A-	9518609	13-07-95
WO-A-9518609	13-07-95	AU-A-	4840393	29-03-94
		CA-A-	2077461	01-03-94
		EP-A-	0621895	02-11-94
		EP-A-	0696193	14-02-96
		JP-T-	7500254	12-01-95
		WO-A-	9405777	17-03-94